Journal Article
. 2013 Jul; 210(9):1695-710.
doi: 10.1084/jem.20130579.

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Tyler R Simpson 1 Fubin Li  Welby Montalvo-Ortiz  Manuel A Sepulveda  Katharina Bergerhoff  Frederick Arce  Claire Roddie  Jake Y Henry  Hideo Yagita  Jedd D Wolchok  Karl S Peggs  Jeffrey V Ravetch  James P Allison  Sergio A Quezada  
  • PMID: 23897981
  •     60 References
  •     603 citations


Treatment with monoclonal antibody specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activity involving blockade of the inhibitory activity of CTLA-4 on both effector (T eff) and regulatory (T reg) T cells, resulting in enhanced antitumor effector T cell activity capable of inducing tumor regression. We demonstrate, however, that the activity of anti-CTLA-4 antibody on the T reg cell compartment is mediated via selective depletion of T reg cells within tumor lesions. Importantly, T reg cell depletion is dependent on the presence of Fcγ receptor-expressing macrophages within the tumor microenvironment, indicating that T reg cells are depleted in trans in a context-dependent manner. Our results reveal further mechanistic insight into the activity of anti-CTLA-4-based cancer immunotherapy, and illustrate the importance of specific features of the local tumor environment on the final outcome of antibody-based immunomodulatory therapies.

Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
Yasuhito Hamaguchi, Yan Xiu, +2 authors, Thomas F Tedder.
J Exp Med, 2006 Mar 08; 203(3). PMID: 16520392    Free PMC article.
Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV.
Marielle A Otten, Gerben J van der Bij, +5 authors, Marjolein van Egmond.
J Immunol, 2008 Nov 05; 181(10). PMID: 18981101
Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III.
L Fossati-Jimack, A Ioan-Facsinay, +10 authors, S Izui.
J Exp Med, 2000 Apr 19; 191(8). PMID: 10770797    Free PMC article.
CTLA-4 control over Foxp3+ regulatory T cell function.
Kajsa Wing, Yasushi Onishi, +5 authors, Shimon Sakaguchi.
Science, 2008 Oct 11; 322(5899). PMID: 18845758
Highly Cited.
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.
Sergio A Quezada, Karl S Peggs, +3 authors, James P Allison.
J Exp Med, 2008 Aug 30; 205(9). PMID: 18725522    Free PMC article.
Highly Cited.
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.
Ying Xie, Akgül Akpinarli, +6 authors, Paul Andrew Antony.
J Exp Med, 2010 Feb 17; 207(3). PMID: 20156973    Free PMC article.
Highly Cited.
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.
Michael A Curran, James P Allison.
Cancer Res, 2009 Sep 10; 69(19). PMID: 19738077    Free PMC article.
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
F Stephen Hodi, Marcus Butler, +17 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2008 Feb 22; 105(8). PMID: 18287062    Free PMC article.
Highly Cited.
The coordination of signaling during Fc receptor-mediated phagocytosis.
Joel A Swanson, Adam D Hoppe.
J Leukoc Biol, 2004 Oct 07; 76(6). PMID: 15466916
Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.
Thomas F Tedder, Aris Baras, Yan Xiu.
Springer Semin Immunopathol, 2006 Nov 09; 28(4). PMID: 17091246
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.
Xuyu Zhou, Samantha L Bailey-Bucktrout, +6 authors, Jeffrey A Bluestone.
Nat Immunol, 2009 Jul 28; 10(9). PMID: 19633673    Free PMC article.
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
A van Elsas, A A Hurwitz, J P Allison.
J Exp Med, 1999 Aug 03; 190(3). PMID: 10430624    Free PMC article.
Highly Cited.
Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Katjana Klages, Christian T Mayer, +7 authors, Tim Sparwasser.
Cancer Res, 2010 Oct 07; 70(20). PMID: 20924102
Highly Cited.
Fcgamma receptors as regulators of immune responses.
Falk Nimmerjahn, Jeffrey V Ravetch.
Nat Rev Immunol, 2007 Dec 08; 8(1). PMID: 18064051
Highly Cited. Review.
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.
Sergio A Quezada, Karl S Peggs, Tyler R Simpson, James P Allison.
Immunol Rev, 2011 Apr 15; 241(1). PMID: 21488893    Free PMC article.
Highly Cited. Review.
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Yutaka Kanda, Tsuyoshi Yamada, +9 authors, Mitsuo Satoh.
Glycobiology, 2006 Oct 03; 17(1). PMID: 17012310
Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection.
Ariela Benigni, Susanna Tomasoni, +10 authors, Giuseppe Remuzzi.
J Am Soc Nephrol, 2006 Apr 28; 17(6). PMID: 16641148
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
R P Sutmuller, L M van Duivenvoorde, +6 authors, C J Melief.
J Exp Med, 2001 Sep 19; 194(6). PMID: 11560997    Free PMC article.
Highly Cited.
IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes.
Yongqing Li, Cassian Yee.
Blood, 2007 Oct 09; 111(1). PMID: 17921346    Free PMC article.
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.
Jason D Fontenot, Marc A Gavin, Alexander Y Rudensky.
Nat Immunol, 2003 Mar 04; 4(4). PMID: 12612578
Highly Cited.
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.
Ezogelin Oflazoglu, Ivan J Stone, +4 authors, Hans-Peter Gerber.
Blood, 2007 Oct 03; 110(13). PMID: 17909075
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
Brian Kavanagh, Shaun O'Brien, +6 authors, Lawrence Fong.
Blood, 2008 Jun 05; 112(4). PMID: 18523152    Free PMC article.
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.
M E Reff, K Carner, +6 authors, D R Anderson.
Blood, 1994 Jan 15; 83(2). PMID: 7506951
Highly Cited.
Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.
B Stockmeyer, D Elsässer, +5 authors, T Valerius.
J Immunol Methods, 2001 Feb 27; 248(1-2). PMID: 11223072
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo.
Falk Nimmerjahn, Anja Lux, +5 authors, Jeffrey V Ravetch.
Proc Natl Acad Sci U S A, 2010 Oct 27; 107(45). PMID: 20974962    Free PMC article.
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.
S Read, V Malmström, F Powrie.
J Exp Med, 2000 Jul 19; 192(2). PMID: 10899916    Free PMC article.
Highly Cited.
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival.
Richard W Griffiths, Eyad Elkord, +4 authors, Robert E Hawkins.
Cancer Immunol Immunother, 2007 May 10; 56(11). PMID: 17487490
FcR gamma chain deletion results in pleiotrophic effector cell defects.
T Takai, M Li, +2 authors, J V Ravetch.
Cell, 1994 Feb 11; 76(3). PMID: 8313472
Highly Cited.
Phagocytosis: elegant complexity.
Lynda M Stuart, R Alan B Ezekowitz.
Immunity, 2005 May 17; 22(5). PMID: 15894272
Highly Cited. Review.
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice.
Jeong M Kim, Jeffrey P Rasmussen, Alexander Y Rudensky.
Nat Immunol, 2006 Dec 01; 8(2). PMID: 17136045
Highly Cited.
Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy.
David Coe, Shaima Begom, +3 authors, Jian-Guo Chai.
Cancer Immunol Immunother, 2010 May 19; 59(9). PMID: 20480365
The microglia/macrophage response in the neonatal rat facial nucleus following axotomy.
M B Graeber, F López-Redondo, +5 authors, S Kohsaka.
Brain Res, 1998 Dec 05; 813(2). PMID: 9838143
Tumor-specific Th17-polarized cells eradicate large established melanoma.
Pawel Muranski, Andrea Boni, +14 authors, Nicholas P Restifo.
Blood, 2008 Mar 21; 112(2). PMID: 18354038    Free PMC article.
Highly Cited.
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.
Junji Uchida, Yasuhito Hamaguchi, +4 authors, Thomas F Tedder.
J Exp Med, 2004 Jun 24; 199(12). PMID: 15210744    Free PMC article.
Highly Cited.
FcgammaRIV: a novel FcR with distinct IgG subclass specificity.
Falk Nimmerjahn, Pierre Bruhns, Ken Horiuchi, Jeffrey V Ravetch.
Immunity, 2005 Jul 26; 23(1). PMID: 16039578
Highly Cited.
Fc receptors are required in passive and active immunity to melanoma.
R Clynes, Y Takechi, +2 authors, J V Ravetch.
Proc Natl Acad Sci U S A, 1998 Jan 22; 95(2). PMID: 9435247    Free PMC article.
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.
Rebecca Waitz, Stephen B Solomon, +4 authors, James P Allison.
Cancer Res, 2011 Nov 24; 72(2). PMID: 22108823    Free PMC article.
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.
M F Krummel, J P Allison.
J Exp Med, 1996 Jun 01; 183(6). PMID: 8676074    Free PMC article.
Highly Cited.
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Sergio A Quezada, Karl S Peggs, Michael A Curran, James P Allison.
J Clin Invest, 2006 Jun 17; 116(7). PMID: 16778987    Free PMC article.
Highly Cited.
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.
Sergio A Quezada, Tyler R Simpson, +9 authors, James P Allison.
J Exp Med, 2010 Feb 17; 207(3). PMID: 20156971    Free PMC article.
Highly Cited.
Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity.
Emily M Schmidt, Chun Jing Wang, +7 authors, Lucy S K Walker.
J Immunol, 2008 Dec 26; 182(1). PMID: 19109158
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Complement and cellular cytotoxicity in antibody therapy of cancer.
Siao-Yi Wang, George Weiner.
Expert Opin Biol Ther, 2008 May 15; 8(6). PMID: 18476787
Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies.
Angela Giorgini, Heather J Brown, +5 authors, Michael G Robson.
J Immunol, 2008 Dec 04; 181(12). PMID: 19050295    Free PMC article.
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
Hong Chen, Chrysoula I Liakou, +8 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2009 Feb 10; 106(8). PMID: 19202079    Free PMC article.
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
Karl S Peggs, Sergio A Quezada, +2 authors, James P Allison.
J Exp Med, 2009 Jul 08; 206(8). PMID: 19581407    Free PMC article.
Highly Cited.
Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer.
Aoshuang Chen, Shanrong Liu, +2 authors, Guoxing Zheng.
Cancer Res, 2007 Feb 07; 67(3). PMID: 17283166
Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.
Tricia A Moo-Young, Justin W Larson, +5 authors, David C Linehan.
J Immunother, 2009 Mar 25; 32(1). PMID: 19307989    Free PMC article.
Ly6G+ neutrophils are dispensable for defense against systemic Listeria monocytogenes infection.
Chao Shi, Tobias M Hohl, +3 authors, Eric G Pamer.
J Immunol, 2011 Oct 07; 187(10). PMID: 21976773    Free PMC article.
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo.
Simon Read, Rebecca Greenwald, +5 authors, Fiona Powrie.
J Immunol, 2006 Sep 20; 177(7). PMID: 16982872    Free PMC article.
Highly Cited.
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.
Silvia Piconese, Barbara Valzasina, Mario P Colombo.
J Exp Med, 2008 Mar 26; 205(4). PMID: 18362171    Free PMC article.
Highly Cited.
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype.
Daniel Hirschhorn-Cymerman, Sadna Budhu, +10 authors, Jedd D Wolchok.
J Exp Med, 2012 Sep 26; 209(11). PMID: 23008334    Free PMC article.
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
Chrysoula I Liakou, Ashish Kamat, +5 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2008 Sep 27; 105(39). PMID: 18818309    Free PMC article.
Highly Cited.
CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.
P Shrikant, A Khoruts, M F Mescher.
Immunity, 1999 Nov 05; 11(4). PMID: 10549630
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.
T Takahashi, T Tagami, +5 authors, S Sakaguchi.
J Exp Med, 2000 Jul 19; 192(2). PMID: 10899917    Free PMC article.
Highly Cited.
In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes.
Yulius Y Setiady, Jennifer A Coccia, Peter U Park.
Eur J Immunol, 2009 Dec 30; 40(3). PMID: 20039297
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
Paul A Antony, Ciriaco A Piccirillo, +9 authors, Nicholas P Restifo.
J Immunol, 2005 Feb 25; 174(5). PMID: 15728465    Free PMC article.
Highly Cited.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies.
Jeong M Kim, Avi Ashkenazi.
J Exp Med, 2013 Aug 28; 210(9). PMID: 23980122    Free PMC article.
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy.
Paula D Bos, George Plitas, +2 authors, Alexander Y Rudensky.
J Exp Med, 2013 Oct 16; 210(11). PMID: 24127486    Free PMC article.
Highly Cited.
Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo.
Fubin Li, Jeffrey V Ravetch.
Proc Natl Acad Sci U S A, 2013 Nov 13; 110(48). PMID: 24218606    Free PMC article.
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu.
Andre Kunert, Trudy Straetemans, +4 authors, Reno Debets.
Front Immunol, 2013 Nov 23; 4. PMID: 24265631    Free PMC article.
Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection.
Johannes Vom Berg, Melissa Vrohlings, +5 authors, Burkhard Becher.
J Exp Med, 2013 Nov 28; 210(13). PMID: 24277150    Free PMC article.
Highly Cited.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Christine Feig, James O Jones, +12 authors, Douglas T Fearon.
Proc Natl Acad Sci U S A, 2013 Nov 28; 110(50). PMID: 24277834    Free PMC article.
Highly Cited.
Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Lee P Richman, Robert H Vonderheide.
Cancer Immunol Res, 2014 Jan 15; 2(1). PMID: 24416732    Free PMC article.
Immunotherapy for prostate cancer: recent developments and future challenges.
Michael T Schweizer, Charles G Drake.
Cancer Metastasis Rev, 2014 Jan 31; 33(2-3). PMID: 24477411    Free PMC article.
Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.
Juan Carlos Almagro, Gary L Gilliland, +21 authors, Kai Y Xu.
MAbs, 2014 Mar 05; 6(3). PMID: 24589717    Free PMC article.
Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.
David Escors.
New J Sci, 2014 Mar 19; 2014. PMID: 24634791    Free PMC article.
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.
Xiaozhou Fan, Sergio A Quezada, +2 authors, James P Allison.
J Exp Med, 2014 Apr 02; 211(4). PMID: 24687957    Free PMC article.
Highly Cited.
Intratumoral immunization: a new paradigm for cancer therapy.
Aurélien Marabelle, Holbrook Kohrt, Christophe Caux, Ronald Levy.
Clin Cancer Res, 2014 Apr 03; 20(7). PMID: 24691639    Free PMC article.
Highly Cited.
VISTA Regulates the Development of Protective Antitumor Immunity.
Isabelle Le Mercier, Wenna Chen, +5 authors, Li Wang.
Cancer Res, 2014 Apr 03; 74(7). PMID: 24691994    Free PMC article.
Highly Cited.
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
Linda C Sandin, Fredrik Eriksson, +3 authors, Sara M Mangsbo.
Oncoimmunology, 2014 Apr 05; 3(1). PMID: 24701377    Free PMC article.
Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation.
Kate S Smigiel, Shivani Srivastava, J Michael Stolley, Daniel J Campbell.
Immunol Rev, 2014 Apr 10; 259(1). PMID: 24712458    Free PMC article.
Highly Cited. Review.
Reply: Regulatory T cells-an important target for cancer immunotherapy.
Charles G Drake, Evan J Lipson, Julie R Brahmer.
Nat Rev Clin Oncol, 2014 May 02; 11(6). PMID: 24781414    Free PMC article.
Regulatory T cells-an important target for cancer immunotherapy.
Jae Il Shin, Sang-Jun Ha.
Nat Rev Clin Oncol, 2014 May 02; 11(6). PMID: 24781417
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.
Francesca Avogadri, Roberta Zappasodi, +8 authors, Taha Merghoub.
Cancer Immunol Res, 2014 May 06; 2(5). PMID: 24795357    Free PMC article.
Enhancement of T cell recruitment and infiltration into tumours.
C Oelkrug, J M Ramage.
Clin Exp Immunol, 2014 May 16; 178(1). PMID: 24828133    Free PMC article.
Rational combinations of immunotherapeutics that target discrete pathways.
Stefani Spranger, Thomas Gajewski.
J Immunother Cancer, 2013 Jan 01; 1. PMID: 24829752    Free PMC article.
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.
Stefani Spranger, Holly K Koblish, +3 authors, Thomas F Gajewski.
J Immunother Cancer, 2014 May 16; 2. PMID: 24829760    Free PMC article.
Highly Cited.
The origins and functions of dendritic cells and macrophages in the skin.
Bernard Malissen, Samira Tamoutounour, Sandrine Henri.
Nat Rev Immunol, 2014 May 24; 14(6). PMID: 24854591
Highly Cited. Review.
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.
Edward Cha, Mark Klinger, +4 authors, Lawrence Fong.
Sci Transl Med, 2014 May 30; 6(238). PMID: 24871131    Free PMC article.
Highly Cited.
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.
Yi-Chi M Kong, Jeffrey C Flynn.
Front Immunol, 2014 Jun 07; 5. PMID: 24904570    Free PMC article.
Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies.
Ronald P Taylor, Margaret A Lindorfer.
Mol Pharmacol, 2014 Jun 20; 86(5). PMID: 24944188    Free PMC article.
The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.
Delia Nelson, Scott Fisher, Bruce Robinson.
J Immunol Res, 2014 Jun 24; 2014. PMID: 24955376    Free PMC article.
Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).
Sadek Malas, Micaela Harrasser, Katie E Lacy, Sophia N Karagiannis.
Oncol Rep, 2014 Jun 28; 32(3). PMID: 24969320    Free PMC article.
Therapeutic vaccines for cancer: an overview of clinical trials.
Ignacio Melero, Gustav Gaudernack, +8 authors, Håkan Mellstedt.
Nat Rev Clin Oncol, 2014 Jul 09; 11(9). PMID: 25001465
Highly Cited. Review.
Type I and type II Fc receptors regulate innate and adaptive immunity.
Andrew Pincetic, Stylianos Bournazos, +5 authors, Jeffrey V Ravetch.
Nat Immunol, 2014 Jul 22; 15(8). PMID: 25045879    Free PMC article.
Highly Cited. Review.
Antibody-based depletion of Foxp3+ T cells potentiates antitumor immune memory stimulated by mTOR inhibition.
Hyung L Kim.
Oncoimmunology, 2014 Aug 02; 3. PMID: 25083329    Free PMC article.
Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion.
Robert L Ferris, Binfeng Lu, Lawrence P Kane.
J Immunol, 2014 Aug 03; 193(4). PMID: 25086175    Free PMC article.
Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.
Miguel F Sanmamed, Lieping Chen.
Cancer J, 2014 Aug 08; 20(4). PMID: 25098285    Free PMC article.
Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.
Mikiya Ishihara, Naohiro Seo, +5 authors, Hiroshi Shiku.
PLoS One, 2014 Aug 12; 9(8). PMID: 25105508    Free PMC article.
Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection.
Pablo Penaloza-MacMaster, Alice O Kamphorst, +10 authors, Rafi Ahmed.
J Exp Med, 2014 Aug 13; 211(9). PMID: 25113973    Free PMC article.
Highly Cited.
Integrative biology of T cell activation.
Bernard Malissen, Claude Grégoire, Marie Malissen, Romain Roncagalli.
Nat Immunol, 2014 Aug 20; 15(9). PMID: 25137453
Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.
Min Dai, Yuen Yee Yip, Ingegerd Hellstrom, Karl Erik Hellstrom.
Clin Cancer Res, 2014 Aug 22; 21(5). PMID: 25142145    Free PMC article.
Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses.
Shiho Chiba, Hiroaki Ikushima, +9 authors, Tadatsugu Taniguchi.
Elife, 2014 Aug 26; 3. PMID: 25149452    Free PMC article.
Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.
B Harpreet Singh, James L Gulley.
Ther Adv Vaccines, 2014 Sep 02; 2(5). PMID: 25177493    Free PMC article.
Neoadjuvant anti-tumor vaccination prior to surgery enhances survival.
Scott A Fisher, Amanda Cleaver, +6 authors, Richard A Lake.
J Transl Med, 2014 Sep 05; 12. PMID: 25186961    Free PMC article.
Cancer immunotherapy in clinical practice -- the past, present, and future.
Gaurav Goel, Weijing Sun.
Chin J Cancer, 2014 Sep 06; 33(9). PMID: 25189717    Free PMC article.
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.
Li Wang, Isabelle Le Mercier, +7 authors, Randolph J Noelle.
Proc Natl Acad Sci U S A, 2014 Oct 01; 111(41). PMID: 25267631    Free PMC article.
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Stephanie R Jackson, Jinyun Yuan, Ryan M Teague.
Immunotherapy, 2014 Oct 08; 6(7). PMID: 25290416    Free PMC article.
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.
Kristina M Ilieva, Isabel Correa, +8 authors, Sophia N Karagiannis.
Mol Cancer Ther, 2014 Nov 12; 13(12). PMID: 25385327    Free PMC article.
CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
Mustafa Diken, Sebastian Boegel, +6 authors, Sebastian Kreiter.
Hum Vaccin Immunother, 2014 Dec 09; 10(10). PMID: 25483671    Free PMC article.
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.
Ann L White, H T Claude Chan, +15 authors, Martin J Glennie.
Cancer Cell, 2014 Dec 17; 27(1). PMID: 25500122    Free PMC article.
Novel immunotherapies for hematologic malignancies.
Michelle H Nelson, Chrystal M Paulos.
Immunol Rev, 2014 Dec 17; 263(1). PMID: 25510273    Free PMC article.
Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells.
Melissa M Berrien-Elliott, Jinyun Yuan, +4 authors, Ryan M Teague.
Cancer Immunol Res, 2014 Dec 18; 3(2). PMID: 25516478    Free PMC article.
Cutting edge: epigenetic regulation of Foxp3 defines a stable population of CD4+ regulatory T cells in tumors from mice and humans.
Jeremy D Waight, Shinji Takai, +9 authors, Nicholas S Wilson.
J Immunol, 2014 Dec 31; 194(3). PMID: 25548231    Free PMC article.
Induced expression of FcγRIIIa (CD16a) on CD4+ T cells triggers generation of IFN-γhigh subset.
Anil K Chauhan, Chen Chen, Terry L Moore, Richard J DiPaolo.
J Biol Chem, 2015 Jan 06; 290(8). PMID: 25556651    Free PMC article.
Confusing signals: recent progress in CTLA-4 biology.
Lucy S K Walker, David M Sansom.
Trends Immunol, 2015 Jan 15; 36(2). PMID: 25582039    Free PMC article.
Highly Cited. Review.
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Dalil Hannani, Marie Vétizou, +30 authors, Laurence Zitvogel.
Cell Res, 2015 Jan 15; 25(2). PMID: 25582080    Free PMC article.
Highly Cited.
New insights into the mechanism of action of immune checkpoint antibodies.
Aurélien Marabelle, Holbrook Kohrt, Ronald Levy.
Oncoimmunology, 2015 Jan 23; 3(8). PMID: 25610751    Free PMC article.
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.
Weiqing Jing, Jill A Gershan, +4 authors, Bryon D Johnson.
J Immunother Cancer, 2015 Jan 24; 3(1). PMID: 25614821    Free PMC article.
A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells.
Tie Zheng Hou, Omar S Qureshi, +4 authors, David M Sansom.
J Immunol, 2015 Jan 30; 194(5). PMID: 25632005    Free PMC article.
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
J Gao, Q He, +6 authors, P Sharma.
Oncogene, 2015 Feb 11; 34(43). PMID: 25659583    Free PMC article.
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Rafael Winograd, Katelyn T Byrne, +8 authors, Robert H Vonderheide.
Cancer Immunol Res, 2015 Feb 14; 3(4). PMID: 25678581    Free PMC article.
Highly Cited.
Antibody effector functions mediated by Fcγ-receptors are compromised during persistent viral infection.
Andreas Wieland, Rangaiah Shashidharamurthy, +9 authors, Rafi Ahmed.
Immunity, 2015 Feb 15; 42(2). PMID: 25680276    Free PMC article.
Targeting the tumor microenvironment to enhance antitumor immune responses.
Kevin Van der Jeught, Lukasz Bialkowski, +7 authors, Karine Breckpot.
Oncotarget, 2015 Feb 16; 6(3). PMID: 25682197    Free PMC article.
Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair.
Dietmar M W Zaiss, William C Gause, Lisa C Osborne, David Artis.
Immunity, 2015 Feb 19; 42(2). PMID: 25692699    Free PMC article.
Highly Cited. Review.
The interaction of anticancer therapies with tumor-associated macrophages.
Alberto Mantovani, Paola Allavena.
J Exp Med, 2015 Mar 11; 212(4). PMID: 25753580    Free PMC article.
Highly Cited. Review.
Haematological malignancies: at the forefront of immunotherapeutic innovation.
Pavan Bachireddy, Ute E Burkhardt, Mohini Rajasagi, Catherine J Wu.
Nat Rev Cancer, 2015 Mar 20; 15(4). PMID: 25786696    Free PMC article.
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Kathleen M Mahoney, Gordon J Freeman, David F McDermott.
Clin Ther, 2015 Apr 01; 37(4). PMID: 25823918    Free PMC article.
Highly Cited. Review.
CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.
Hyun-Bae Jie, Patrick J Schuler, +5 authors, Robert L Ferris.
Cancer Res, 2015 Apr 03; 75(11). PMID: 25832655    Free PMC article.
Highly Cited.
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.
Florencia Paula Madorsky Rowdo, Antonela Baron, Mariela Urrutia, José Mordoh.
Front Immunol, 2015 Apr 11; 6. PMID: 25859247    Free PMC article.
Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
Camille Guillerey, Lucas Ferrari de Andrade, +12 authors, Ludovic Martinet.
J Clin Invest, 2015 Apr 22; 125(5). PMID: 25893601    Free PMC article.
Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis.
Haiming Yu, Junlan Yang, +3 authors, Jiandong Wang.
Cancer Immunol Immunother, 2015 Apr 22; 64(7). PMID: 25893809    Free PMC article.
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Emanuela Romano, Monika Kusio-Kobialka, +7 authors, Daniel E Speiser.
Proc Natl Acad Sci U S A, 2015 Apr 29; 112(19). PMID: 25918390    Free PMC article.
Highly Cited.
OECI-EACR precision medicine for cancer: Conference report 1-4 March 2015, Luxembourg.
Anna Golebiewska, Sabrina Fritah, Maria Romina Girotti.
Ecancermedicalscience, 2015 May 02; 9. PMID: 25932043    Free PMC article.
An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Michelle Kinder, Allison R Greenplate, +2 authors, Randall J Brezski.
MAbs, 2015 May 02; 7(3). PMID: 25933349    Free PMC article.
Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice.
Andrés H Rossi, Ana Farias, +3 authors, Paula M Berguer.
PLoS One, 2015 May 15; 10(5). PMID: 25973756    Free PMC article.
Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.
A Doran Bostwick, April K Salama, Brent A Hanks.
J Immunother Cancer, 2015 May 21; 3. PMID: 25992290    Free PMC article.
Inhibitory receptors as targets for cancer immunotherapy.
Meghan E Turnis, Lawrence P Andrews, Dario A A Vignali.
Eur J Immunol, 2015 May 29; 45(7). PMID: 26018646    Free PMC article.
Beyond adjuvants: immunomodulation strategies to enhance T cell immunity.
Alice O Kamphorst, Koichi Araki, Rafi Ahmed.
Vaccine, 2015 May 30; 33 Suppl 2. PMID: 26022562    Free PMC article.
In-situ tumor vaccination: Bringing the fight to the tumor.
Robert H Pierce, Jean S Campbell, +2 authors, Holbrook E K Kohrt.
Hum Vaccin Immunother, 2015 Jun 10; 11(8). PMID: 26055074    Free PMC article.
Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.
Shannon K Quirk, Anna K Shure, Devendra K Agrawal.
Transl Res, 2015 Jun 30; 166(5). PMID: 26118951    Free PMC article.
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.
Claire Vanpouille-Box, Karsten A Pilones, +2 authors, Sandra Demaria.
Vaccine, 2015 Jul 08; 33(51). PMID: 26148880    Free PMC article.
Clinical Development of Immune Checkpoint Inhibitors.
Ayumu Ito, Shunsuke Kondo, Kohei Tada, Shigehisa Kitano.
Biomed Res Int, 2015 Jul 15; 2015. PMID: 26161407    Free PMC article.
Inhibitory Receptors Beyond T Cell Exhaustion.
Silvia A Fuertes Marraco, Natalie J Neubert, Grégory Verdeil, Daniel E Speiser.
Front Immunol, 2015 Jul 15; 6. PMID: 26167163    Free PMC article.
Highly Cited. Review.
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Ignacio Melero, David M Berman, +3 authors, John Haanen.
Nat Rev Cancer, 2015 Jul 25; 15(8). PMID: 26205340
Highly Cited. Review.
Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.
J David Peske, Amber B Woods, Victor H Engelhard.
Adv Cancer Res, 2015 Jul 29; 128. PMID: 26216636    Free PMC article.
Combination cancer immunotherapy and new immunomodulatory targets.
Kathleen M Mahoney, Paul D Rennert, Gordon J Freeman.
Nat Rev Drug Discov, 2015 Aug 01; 14(8). PMID: 26228759
Highly Cited. Review.
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
Francesca De Felice, Claudia Marchetti, +4 authors, Pierluigi Benedetti Panici.
J Immunol Res, 2015 Aug 04; 2015. PMID: 26236750    Free PMC article.
Relevance of tumor-infiltrating lymphocytes in breast cancer.
Sathana Dushyanthen, Paul A Beavis, +5 authors, Sherene Loi.
BMC Med, 2015 Aug 25; 13. PMID: 26300242    Free PMC article.
Highly Cited. Review.
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.
Chih-Hao Chang, Jing Qiu, +11 authors, Erika L Pearce.
Cell, 2015 Sep 01; 162(6). PMID: 26321679    Free PMC article.
Highly Cited.
Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
Simon Ville, Nicolas Poirier, Gilles Blancho, Bernard Vanhove.
Front Immunol, 2015 Sep 01; 6. PMID: 26322044    Free PMC article.
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
Elizabeth Buchbinder, F Stephen Hodi.
J Clin Invest, 2015 Sep 02; 125(9). PMID: 26325034    Free PMC article.
Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients.
Tengfei Wei, Jun Zhang, +5 authors, Qian Shen.
Am J Cancer Res, 2015 Sep 04; 5(7). PMID: 26328249    Free PMC article.
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.
Anne Bertrand, Marie Kostine, +2 authors, Thierry Schaeverbeke.
BMC Med, 2015 Sep 05; 13. PMID: 26337719    Free PMC article.
Highly Cited. Systematic Review.
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.
Nikhil S Joshi, Elliot H Akama-Garren, +11 authors, Tyler Jacks.
Immunity, 2015 Sep 06; 43(3). PMID: 26341400    Free PMC article.
Highly Cited.
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.
Todd Bartkowiak, Shailbala Singh, +6 authors, Michael A Curran.
Proc Natl Acad Sci U S A, 2015 Sep 10; 112(38). PMID: 26351680    Free PMC article.
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.
Alison M Paterson, Scott B Lovitch, +9 authors, Arlene H Sharpe.
J Exp Med, 2015 Sep 16; 212(10). PMID: 26371185    Free PMC article.
Highly Cited.
Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.
Alan Serrels, Tom Lund, +15 authors, Margaret C Frame.
Cell, 2015 Sep 26; 163(1). PMID: 26406376    Free PMC article.
Highly Cited.
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
N Yamazaki, H Uhara, +8 authors, T Tokudome.
Cancer Chemother Pharmacol, 2015 Sep 27; 76(5). PMID: 26407818    Free PMC article.
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
N Yamazaki, Y Kiyohara, +8 authors, T Tokudome.
Cancer Chemother Pharmacol, 2015 Sep 28; 76(5). PMID: 26410424    Free PMC article.
TIGIT predominantly regulates the immune response via regulatory T cells.
Sema Kurtulus, Kaori Sakuishi, +6 authors, Ana C Anderson.
J Clin Invest, 2015 Sep 29; 125(11). PMID: 26413872    Free PMC article.
Highly Cited.
Targeting the tumor niche to treat cancer.
Sattva S Neelapu, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2015 Oct 10; 112(42). PMID: 26450879    Free PMC article.
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy.
Kelly Kersten, Camilla Salvagno, Karin E de Visser.
Front Immunol, 2015 Oct 27; 6. PMID: 26500653    Free PMC article.
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.
David A Reardon, Mark R Gilbert, Wolfgang Wick, Linda Liau.
Neuro Oncol, 2015 Oct 31; 17 Suppl 7. PMID: 26516225    Free PMC article.
Cancer immunotherapy: Strategies for personalization and combinatorial approaches.
Vishwanath Sathyanarayanan, Sattva S Neelapu.
Mol Oncol, 2015 Nov 10; 9(10). PMID: 26548534    Free PMC article.
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.
Anna Śledzińska, Laurie Menger, +2 authors, Sergio A Quezada.
Mol Oncol, 2015 Nov 19; 9(10). PMID: 26578451    Free PMC article.
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy.
Vinod Vijay Subhash, Mei Shi Yeo, Woei Loon Tan, Wei Peng Yong.
J Immunol Res, 2015 Nov 19; 2015. PMID: 26579545    Free PMC article.
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.
Roy L Maute, Sydney R Gordon, +10 authors, Aaron M Ring.
Proc Natl Acad Sci U S A, 2015 Nov 26; 112(47). PMID: 26604307    Free PMC article.
Highly Cited.
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Ivan Márquez-Rodas, Pablo Cerezuela, +4 authors, Salvador Martín-Algarra.
Ann Transl Med, 2015 Nov 26; 3(18). PMID: 26605313    Free PMC article.
Melanoma: oncogenic drivers and the immune system.
Niki Karachaliou, Sara Pilotto, +10 authors, Rafael Rosell.
Ann Transl Med, 2015 Nov 26; 3(18). PMID: 26605311    Free PMC article.
Immune suppressive mechanisms in the tumor microenvironment.
David H Munn, Vincenzo Bronte.
Curr Opin Immunol, 2015 Nov 27; 39. PMID: 26609943    Free PMC article.
Highly Cited. Review.
Enzyme-Mediated Modification of Single-Domain Antibodies for Imaging Modalities with Different Characteristics.
Mohammad Rashidian, Lu Wang, +7 authors, Steven H Liang.
Angew Chem Int Ed Engl, 2015 Dec 03; 55(2). PMID: 26630549    Free PMC article.
Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication.
Omar A Ali, Sarah A Lewin, Glenn Dranoff, David J Mooney.
Cancer Immunol Res, 2015 Dec 17; 4(2). PMID: 26669718    Free PMC article.
Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells.
Stephanie Vogel, Elena Grabski, +12 authors, Ulrich Kalinke.
Sci Rep, 2015 Dec 17; 5. PMID: 26670584    Free PMC article.
New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
Ali Ghasemzadeh, Trinity J Bivalacqua, Noah M Hahn, Charles G Drake.
Clin Cancer Res, 2015 Dec 20; 22(4). PMID: 26683632    Free PMC article.
Influence of immunoglobulin isotype on therapeutic antibody function.
Stephen A Beers, Martin J Glennie, Ann L White.
Blood, 2016 Jan 15; 127(9). PMID: 26764357    Free PMC article.
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Jianda Yuan, Priti S Hegde, +16 authors, Bernard A Fox.
J Immunother Cancer, 2016 Jan 21; 4. PMID: 26788324    Free PMC article.
Highly Cited. Review.
The role of microbiota in cancer therapy.
Ernesto Perez-Chanona, Giorgio Trinchieri.
Curr Opin Immunol, 2016 Jan 29; 39. PMID: 26820225    Free PMC article.
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Joseph M Ryan, Jeffrey S Wasser, Adam J Adler, Anthony T Vella.
Expert Opin Biol Ther, 2016 Feb 09; 16(5). PMID: 26855028    Free PMC article.
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
Paola Savoia, Chiara Astrua, Paolo Fava.
Hum Vaccin Immunother, 2016 Feb 19; 12(5). PMID: 26889818    Free PMC article.
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
Angela K B Alme, Beerinder S Karir, Bishoy M Faltas, Charles G Drake.
Urol Oncol, 2016 Mar 01; 34(4). PMID: 26923782    Free PMC article.
T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway.
Jose-Ignacio Rodriguez-Barbosa, Carlos Fernandez-Renedo, +2 authors, Maria-Luisa Del Rio.
Cell Mol Immunol, 2016 Mar 01; 14(6). PMID: 26924526    Free PMC article.
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.
Weiping Zou, Jedd D Wolchok, Lieping Chen.
Sci Transl Med, 2016 Mar 05; 8(328). PMID: 26936508    Free PMC article.
Highly Cited. Review.
Tumor-associated macrophages and anti-tumor therapies: complex links.
Cristina Belgiovine, Maurizio D'Incalci, Paola Allavena, Roberta Frapolli.
Cell Mol Life Sci, 2016 Mar 10; 73(13). PMID: 26956893
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
Danny N Khalil, Eric L Smith, Renier J Brentjens, Jedd D Wolchok.
Nat Rev Clin Oncol, 2016 Mar 16; 13(5). PMID: 26977780    Free PMC article.
Highly Cited. Review.
Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7.
Matthew M Halpert, Vanaja Konduri, +5 authors, William K Decker.
Stem Cells Dev, 2016 Mar 17; 25(10). PMID: 26979751    Free PMC article.
T cell receptor signalling in the control of regulatory T cell differentiation and function.
Ming O Li, Alexander Y Rudensky.
Nat Rev Immunol, 2016 Mar 31; 16(4). PMID: 27026074    Free PMC article.
Highly Cited. Review.
OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.
Chester Lai, Suzannah August, +9 authors, Eugene Healy.
Clin Cancer Res, 2016 Apr 02; 22(16). PMID: 27034329    Free PMC article.
Tremelimumab: research and clinical development.
Begoña Comin-Anduix, Helena Escuin-Ordinas, Francisco Javier Ibarrondo.
Onco Targets Ther, 2016 Apr 05; 9. PMID: 27042127    Free PMC article.
Emerging Opportunities and Challenges in Cancer Immunotherapy.
Theresa L Whiteside, Sandra Demaria, +2 authors, Ignacio Melero.
Clin Cancer Res, 2016 Apr 17; 22(8). PMID: 27084738    Free PMC article.
Highly Cited. Review.
Reversing T-cell Dysfunction and Exhaustion in Cancer.
Hassane M Zarour.
Clin Cancer Res, 2016 Apr 17; 22(8). PMID: 27084739    Free PMC article.
Highly Cited. Review.
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model.
De-Kuan Chang, Eric Peterson, +6 authors, Wayne A Marasco.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141347    Free PMC article.
Targeting immunosuppression by Tregs with monoclonal antibodies against GARP.
Stéphanie Liénart, Julie Stockis, Olivier Dedobbeleer, Sophie Lucas.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141368    Free PMC article.
Roles of regulatory T cells in cancer immunity.
Yoshiko Takeuchi, Hiroyoshi Nishikawa.
Int Immunol, 2016 May 11; 28(8). PMID: 27160722    Free PMC article.
Highly Cited. Review.
Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity.
Hidetoshi Nakagawa, Jessica M Sido, +3 authors, Hye-Jung Kim.
Proc Natl Acad Sci U S A, 2016 May 18; 113(22). PMID: 27185917    Free PMC article.
Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.
Mira A Patel, Jennifer E Kim, +19 authors, Michael Lim.
J Immunother Cancer, 2016 May 18; 4. PMID: 27190629    Free PMC article.
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Lucia Festino, Gerardo Botti, +5 authors, Paolo A Ascierto.
Drugs, 2016 May 28; 76(9). PMID: 27229745
Highly Cited. Review.
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Rony Dahan, Bryan C Barnhart, +3 authors, Jeffrey V Ravetch.
Cancer Cell, 2016 Jun 07; 29(6). PMID: 27265505    Free PMC article.
Highly Cited.
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.
Kristina H Young, Jason R Baird, +9 authors, Marka R Crittenden.
PLoS One, 2016 Jun 10; 11(6). PMID: 27281029    Free PMC article.
Highly Cited.
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
Michal Lotem, Sharon Merims, +19 authors, Tamar Peretz.
J Immunol Res, 2016 Jun 14; 2016. PMID: 27294163    Free PMC article.
Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen.
Yariv Mazor, Chunning Yang, +4 authors, William F Dall'Acqua.
PLoS One, 2016 Jun 21; 11(6). PMID: 27322177    Free PMC article.
The role of myeloid cells in cancer therapies.
Camilla Engblom, Christina Pfirschke, Mikael J Pittet.
Nat Rev Cancer, 2016 Jun 25; 16(7). PMID: 27339708
Highly Cited. Review.
CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Zhenhua Ren, Jingya Guo, +7 authors, Yang-Xin Fu.
Clin Cancer Res, 2016 Jun 30; 23(1). PMID: 27354469    Free PMC article.
CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.
Lena M Kranz, Matthias Birtel, +7 authors, Mustafa Diken.
Hum Vaccin Immunother, 2016 Jul 21; 12(11). PMID: 27435168    Free PMC article.
Immuno-oncology combinations: raising the tail of the survival curve.
Samuel J Harris, Jessica Brown, Juanita Lopez, Timothy A Yap.
Cancer Biol Med, 2016 Jul 28; 13(2). PMID: 27458526    Free PMC article.
CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma.
Guang-Tao Yu, Lin-Lin Bu, +5 authors, Zhi-Jun Sun.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471622    Free PMC article.
SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.
Wei Xue, Rachael L Metheringham, +5 authors, Lindy G Durrant.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471648    Free PMC article.
CD28 co-stimulation in T-cell homeostasis: a recent perspective.
Niklas Beyersdorf, Thomas Kerkau, Thomas Hünig.
Immunotargets Ther, 2015 Jan 01; 4. PMID: 27471717    Free PMC article.
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
Teofila Seremet, Alexander Koch, +12 authors, Bart Neyns.
J Transl Med, 2016 Aug 04; 14(1). PMID: 27484791    Free PMC article.
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.
Lewis Zhichang Shi, Tihui Fu, +7 authors, Padmanee Sharma.
Nat Commun, 2016 Aug 09; 7. PMID: 27498556    Free PMC article.
Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Amy E Moran, Fanny Polesso, Andrew D Weinberg.
J Immunol, 2016 Aug 10; 197(6). PMID: 27503208    Free PMC article.
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma.
Todd Crocenzi, Benjamin Cottam, +12 authors, Marka R Crittenden.
J Immunother Cancer, 2016 Aug 18; 4. PMID: 27532020    Free PMC article.
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.
Heather L McArthur, Adi Diab, +27 authors, Larry Norton.
Clin Cancer Res, 2016 Nov 05; 22(23). PMID: 27566765    Free PMC article.
Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity.
Yang-Zhuo Gu, Chuan-Wen Fan, +7 authors, Yu-Quan Wei.
Sci Rep, 2016 Aug 31; 6. PMID: 27571893    Free PMC article.
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.
David B Page, Jianda Yuan, +22 authors, Heather L McArthur.
Cancer Immunol Res, 2016 Sep 03; 4(10). PMID: 27587469    Free PMC article.
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Mark J Selby, John J Engelhardt, +11 authors, Alan J Korman.
PLoS One, 2016 Sep 10; 11(9). PMID: 27610613    Free PMC article.
Highly Cited.
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.
Roch Houot, Philippe Gaulard, +18 authors, Daniel Olive.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622041    Free PMC article.
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
Geoffrey S Williams, Bina Mistry, +20 authors, Robert W Wilkinson.
Oncotarget, 2016 Sep 15; 7(42). PMID: 27626702    Free PMC article.
Current clinical trials testing the combination of immunotherapy with radiotherapy.
Josephine Kang, Sandra Demaria, Silvia Formenti.
J Immunother Cancer, 2016 Sep 24; 4. PMID: 27660705    Free PMC article.
Highly Cited.
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.
Grit S Herter-Sprie, Shohei Koyama, +18 authors, Kwok-Kin Wong.
JCI Insight, 2016 Oct 05; 1(9). PMID: 27699275    Free PMC article.
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.
Peter Ellmark, Sara M Mangsbo, +2 authors, Thomas H Tötterman.
Cancer Immunol Immunother, 2016 Oct 08; 66(1). PMID: 27714433    Free PMC article.
Understanding Immune Cells in Tertiary Lymphoid Organ Development: It Is All Starting to Come Together.
Gareth W Jones, David G Hill, Simon A Jones.
Front Immunol, 2016 Oct 19; 7. PMID: 27752256    Free PMC article.
Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis.
Edurne Arriola, Matthew Wheater, +2 authors, Christian Ottensmeier.
Oncoimmunology, 2016 Oct 21; 5(9). PMID: 27757302    Free PMC article.
The head and neck cancer immune landscape and its immunotherapeutic implications.
Rajarsi Mandal, Yasin Şenbabaoğlu, +8 authors, Luc Gt Morris.
JCI Insight, 2016 Oct 26; 1(17). PMID: 27777979    Free PMC article.
Highly Cited.
Recent advances in understanding antitumor immunity.
Rodrigo Ramella Munhoz, Michael Andrew Postow.
F1000Res, 2016 Nov 03; 5. PMID: 27803807    Free PMC article.
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.
Soumaya Karaki, Marie Anson, +4 authors, Eric Tartour.
Vaccines (Basel), 2016 Nov 10; 4(4). PMID: 27827885    Free PMC article.
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.
Marco De Simone, Alberto Arrigoni, +28 authors, Massimiliano Pagani.
Immunity, 2016 Nov 17; 45(5). PMID: 27851914    Free PMC article.
Highly Cited.
Immune checkpoint therapy for pancreatic cancer.
Henrik Johansson, Roland Andersson, +3 authors, Daniel Ansari.
World J Gastroenterol, 2016 Dec 07; 22(43). PMID: 27920468    Free PMC article.
Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.
Bryan C Barnhart, Michael Quigley.
Immunol Cell Biol, 2016 Dec 16; 95(4). PMID: 27974746
Regulatory T cells in cancer immunotherapy.
Atsushi Tanaka, Shimon Sakaguchi.
Cell Res, 2016 Dec 21; 27(1). PMID: 27995907    Free PMC article.
Highly Cited. Review.
A New VISTA on combination therapy for negative checkpoint regulator blockade.
Jie Deng, Isabelle Le Mercier, Anna Kuta, Randolph J Noelle.
J Immunother Cancer, 2016 Dec 30; 4. PMID: 28031817    Free PMC article.
TCR Signaling and CD28/CTLA-4 Signaling Cooperatively Modulate T Regulatory Cell Homeostasis.
Michael P Holt, George A Punkosdy, Deborah D Glass, Ethan M Shevach.
J Immunol, 2017 Jan 06; 198(4). PMID: 28053234    Free PMC article.
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.
W Joost Lesterhuis, Anthony Bosco, +3 authors, Richard A Lake.
Nat Rev Drug Discov, 2017 Jan 07; 16(4). PMID: 28057932
Highly Cited. Review.
Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Alexander L Rakhmilevich, Mildred Felder, +8 authors, Paul M Sondel.
J Immunol, 2017 Jan 08; 198(4). PMID: 28062694    Free PMC article.
New Immunotherapy Strategies in Breast Cancer.
Lin-Yu Yu, Jie Tang, +4 authors, Xiao-Ping Chen.
Int J Environ Res Public Health, 2017 Jan 14; 14(1). PMID: 28085094    Free PMC article.
Systemic Immunity Is Required for Effective Cancer Immunotherapy.
Matthew H Spitzer, Yaron Carmi, +10 authors, Edgar G Engleman.
Cell, 2017 Jan 24; 168(3). PMID: 28111070    Free PMC article.
Highly Cited.
Tumour-associated macrophages as treatment targets in oncology.
Alberto Mantovani, Federica Marchesi, +2 authors, Paola Allavena.
Nat Rev Clin Oncol, 2017 Jan 25; 14(7). PMID: 28117416    Free PMC article.
Highly Cited. Review.
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.
J Duell, M Dittrich, +8 authors, M S Topp.
Leukemia, 2017 Jan 26; 31(10). PMID: 28119525    Free PMC article.
Highly Cited.
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.
Maria Carmen Ochoa, Luna Minute, +5 authors, Pedro Berraondo.
Immunol Cell Biol, 2017 Feb 01; 95(4). PMID: 28138156
Highly Cited. Review.
Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma.
Antonio Miguel, Luis Sendra, +5 authors, Salvador F Aliño.
Onco Targets Ther, 2017 Feb 09; 10. PMID: 28176947    Free PMC article.
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
A K S Salama, S J Moschos.
Ann Oncol, 2017 Feb 09; 28(1). PMID: 28177433    Free PMC article.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas.
Cell, 2017 Feb 12; 168(4). PMID: 28187290    Free PMC article.
Highly Cited. Review.
Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8+ T cells.
Michael Sun, Ngoc Ha, +7 authors, To-Ha Thai.
Sci Rep, 2017 Feb 22; 7. PMID: 28220815    Free PMC article.
Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1.
Anchana Rathinasamy, Christoph Domschke, +10 authors, Philipp Beckhove.
Cancer Immunol Immunother, 2017 Feb 23; 66(5). PMID: 28224210    Free PMC article.
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer.
Thomas Worzfeld, Elke Pogge von Strandmann, +4 authors, Rolf Müller.
Front Oncol, 2017 Mar 10; 7. PMID: 28275576    Free PMC article.
Highly Cited. Review.
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.
Rossana Tallerico, Costanza M Cristiani, +21 authors, Ennio Carbone.
Oncoimmunology, 2017 Mar 28; 6(2). PMID: 28344869    Free PMC article.
Cancer Immunotherapy: Whence and Whither.
Peter J Stambrook, John Maher, Farzin Farzaneh.
Mol Cancer Res, 2017 Mar 31; 15(6). PMID: 28356330    Free PMC article.
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.
Kirstie L S Cleary, H T Claude Chan, +2 authors, Mark S Cragg.
J Immunol, 2017 Apr 14; 198(10). PMID: 28404636    Free PMC article.
Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer.
Xiaowei Chen, Yoshihiro Takemoto, +9 authors, Timothy C Wang.
Oncoimmunology, 2017 Apr 14; 6(3). PMID: 28405523    Free PMC article.
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Frederick Arce Vargas, Andrew J S Furness, +29 authors, Sergio A Quezada.
Immunity, 2017 Apr 16; 46(4). PMID: 28410988    Free PMC article.
Highly Cited.
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.
Yago Pico de Coaña, Maria Wolodarski, +9 authors, Rolf Kiessling.
Oncotarget, 2017 Apr 21; 8(13). PMID: 28423487    Free PMC article.
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress.
Zin W Myint, Gaurav Goel.
J Hematol Oncol, 2017 Apr 25; 10(1). PMID: 28434400    Free PMC article.
Signaling by Antibodies: Recent Progress.
Stylianos Bournazos, Taia T Wang, +2 authors, Jeffrey V Ravetch.
Annu Rev Immunol, 2017 Apr 28; 35. PMID: 28446061    Free PMC article.
Highly Cited. Review.
Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Bingyu Li, Lijun Xu, +10 authors, Jianmin Fang.
Oncotarget, 2017 Apr 30; 8(24). PMID: 28454118    Free PMC article.
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Udupi A Ramagopal, Weifeng Liu, +10 authors, Steven C Almo.
Proc Natl Acad Sci U S A, 2017 May 10; 114(21). PMID: 28484017    Free PMC article.
Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.
Rodrigo Vazquez-Lombardi, Claudia Loetsch, +8 authors, Daniel Christ.
Nat Commun, 2017 May 13; 8. PMID: 28497796    Free PMC article.
B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment.
Giulia Chiaruttini, Silvia Mele, +4 authors, Sophia N Karagiannis.
Oncoimmunology, 2017 May 17; 6(4). PMID: 28507802    Free PMC article.
Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.
Andrew S Flies, Nicholas B Blackburn, +2 authors, Gregory M Woods.
Front Immunol, 2017 May 19; 8. PMID: 28515726    Free PMC article.
Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.
Dong Sun Oh, Heegon Kim, +4 authors, Heung Kyu Lee.
Oncotarget, 2017 May 26; 8(29). PMID: 28537894    Free PMC article.
Combining radiotherapy with immunotherapy: the past, the present and the future.
Evert J Van Limbergen, Dirk K De Ruysscher, +8 authors, Philippe Lambin.
Br J Radiol, 2017 May 26; 90(1076). PMID: 28541096    Free PMC article.
Delivering safer immunotherapies for cancer.
Lauren Milling, Yuan Zhang, Darrell J Irvine.
Adv Drug Deliv Rev, 2017 May 27; 114. PMID: 28545888    Free PMC article.
Highly Cited. Review.
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.
Jingyu Zhang, Dai Liu, +4 authors, Jennifer D Wu.
Sci Adv, 2017 Jun 01; 3(5). PMID: 28560327    Free PMC article.
PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells.
Carmen Stecher, Claire Battin, +5 authors, Peter Steinberger.
Front Immunol, 2017 Jun 08; 8. PMID: 28588576    Free PMC article.
Immune Checkpoints as a Target for Colorectal Cancer Treatment.
Alessandro Passardi, Matteo Canale, Martina Valgiusti, Paola Ulivi.
Int J Mol Sci, 2017 Jun 22; 18(6). PMID: 28635639    Free PMC article.
Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases.
Dipti Vijayan, Deborah S Barkauskas, +7 authors, Mark J Smyth.
Oncoimmunology, 2017 Jun 24; 6(5). PMID: 28638737    Free PMC article.
Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.
Maher G Nawaf, Maria H Ulvmar, +7 authors, Peter J L Lane.
J Immunol, 2017 Jun 25; 199(3). PMID: 28646041    Free PMC article.
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Casey R Ager, Matthew J Reilley, +3 authors, Michael A Curran.
Cancer Immunol Res, 2017 Jul 05; 5(8). PMID: 28674082    Free PMC article.
Highly Cited.
Chemotherapy and tumor microenvironment of pancreatic cancer.
Qiaofei Liu, Quan Liao, Yupei Zhao.
Cancer Cell Int, 2017 Jul 12; 17. PMID: 28694739    Free PMC article.
Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults.
Rawad Elias, Joshua Morales, Carolyn Presley.
Curr Oncol Rep, 2017 Jul 30; 19(9). PMID: 28755314
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
Clemence Granier, Eleonore De Guillebon, +7 authors, Eric Tartour.
ESMO Open, 2017 Aug 02; 2(2). PMID: 28761757    Free PMC article.
Highly Cited. Review.
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Spencer C Wei, Jacob H Levine, +8 authors, James P Allison.
Cell, 2017 Aug 15; 170(6). PMID: 28803728    Free PMC article.
Highly Cited.
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
Dipongkor Saha, Robert L Martuza, Samuel D Rabkin.
Cancer Cell, 2017 Aug 16; 32(2). PMID: 28810147    Free PMC article.
Highly Cited.
Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
Sadna Budhu, David A Schaer, +8 authors, Jedd D Wolchok.
Sci Signal, 2017 Aug 31; 10(494). PMID: 28851824    Free PMC article.
Localized CD47 blockade enhances immunotherapy for murine melanoma.
Jessica R Ingram, Olga S Blomberg, +8 authors, Michael Dougan.
Proc Natl Acad Sci U S A, 2017 Sep 07; 114(38). PMID: 28874561    Free PMC article.
Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Martin Scurr, Tom Pembroke, +14 authors, Andrew Godkin.
JAMA Oncol, 2017 Sep 08; 3(10). PMID: 28880972    Free PMC article.
PD1 signal transduction pathways in T cells.
Hugo Arasanz, Maria Gato-Cañas, +4 authors, David Escors.
Oncotarget, 2017 Sep 09; 8(31). PMID: 28881701    Free PMC article.
Highly Cited. Review.
Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells.
Paul E Clavijo, Ellen C Moore, +6 authors, Clint T Allen.
Oncotarget, 2017 Sep 17; 8(34). PMID: 28915554    Free PMC article.
EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity.
Diana I Albu, Zichun Wang, +15 authors, Xingfeng Bao.
Oncoimmunology, 2017 Sep 19; 6(8). PMID: 28920002    Free PMC article.
Roles for Innate Immunity in Combination Immunotherapies.
Kelly D Moynihan, Darrell J Irvine.
Cancer Res, 2017 Sep 21; 77(19). PMID: 28928130    Free PMC article.
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.
Pearl Bakhru, Meng-Lei Zhu, +14 authors, Maureen A Su.
JCI Insight, 2017 Sep 22; 2(18). PMID: 28931755    Free PMC article.
CD4 and CD8 T lymphocyte interplay in controlling tumor growth.
Dmitrij Ostroumov, Nora Fekete-Drimusz, +2 authors, Norman Woller.
Cell Mol Life Sci, 2017 Oct 17; 75(4). PMID: 29032503    Free PMC article.
The immune system in cancer metastasis: friend or foe?
Louise M E Janssen, Emma E Ramsay, Craig D Logsdon, Willem W Overwijk.
J Immunother Cancer, 2017 Oct 19; 5(1). PMID: 29037250    Free PMC article.
Highly Cited. Review.
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Michael J E Marshall, Richard J Stopforth, Mark S Cragg.
Front Immunol, 2017 Oct 20; 8. PMID: 29046676    Free PMC article.
Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells.
Shiming Ye, Melvin I Fox, +8 authors, Patricia A Culp.
J Immunol Res, 2017 Oct 28; 2017. PMID: 29075649    Free PMC article.
CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.
Anna Wasiuk, James Testa, +9 authors, Li-Zhen He.
J Immunol, 2017 Nov 08; 199(12). PMID: 29109120    Free PMC article.
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.
Jessica S Brown, Raghav Sundar, Juanita Lopez.
Br J Cancer, 2017 Nov 11; 118(3). PMID: 29123260    Free PMC article.
Highly Cited. Review.
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.
Manisha Singh, Christina Vianden, +15 authors, Willem W Overwijk.
Nat Commun, 2017 Nov 14; 8(1). PMID: 29129918    Free PMC article.
Immune checkpoint inhibitors: new strategies to checkmate cancer.
R A M Wilson, T R J Evans, A R Fraser, R J B Nibbs.
Clin Exp Immunol, 2017 Nov 16; 191(2). PMID: 29139554    Free PMC article.
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.
Robert J Torphy, Richard D Schulick, Yuwen Zhu.
Int J Mol Sci, 2017 Dec 07; 18(12). PMID: 29211042    Free PMC article.
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Michael Dougan.
Front Immunol, 2017 Dec 13; 8. PMID: 29230210    Free PMC article.
Highly Cited. Review.
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H Young.
Front Immunol, 2017 Dec 20; 8. PMID: 29255458    Free PMC article.
Highly Cited. Review.
The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent.
Christopher Bachran, Matthias Schröder, +5 authors, Lee Kim Swee.
Sci Rep, 2017 Dec 22; 7(1). PMID: 29263417    Free PMC article.
Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy.
Shuguang Tan, Catherine W-H Zhang, George F Gao.
Signal Transduct Target Ther, 2017 Dec 22; 1. PMID: 29263905    Free PMC article.
Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model.
Cameron S Field, Martin K Hunn, +3 authors, Ian F Hermans.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296535    Free PMC article.
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models.
Katherine E Lewis, Mark J Selby, +11 authors, Stacey R Dillon.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296539    Free PMC article.
Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.
Neus Martinez-Bosch, Judith Vinaixa, Pilar Navarro.
Cancers (Basel), 2018 Jan 06; 10(1). PMID: 29301364    Free PMC article.
Highly Cited. Review.
Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.
Luigi Cari, Giuseppe Nocentini, Graziella Migliorati, Carlo Riccardi.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308313    Free PMC article.
Unlocking the Complexities of Tumor-Associated Regulatory T Cells.
Jaime L Chao, Peter A Savage.
J Immunol, 2018 Jan 10; 200(2). PMID: 29311383    Free PMC article.
Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
Shivani Srivastava, Stanley R Riddell.
J Immunol, 2018 Jan 10; 200(2). PMID: 29311388    Free PMC article.
Highly Cited. Review.
Mechanisms of resistance to immune checkpoint inhibitors.
Russell W Jenkins, David A Barbie, Keith T Flaherty.
Br J Cancer, 2018 Jan 11; 118(1). PMID: 29319049    Free PMC article.
Highly Cited. Review.
Regulatory T cells (Tregs): A major immune checkpoint to consider in combinatorial therapeutic HIV-1 vaccines.
Audrey Hubert, Nabila Seddiki.
Hum Vaccin Immunother, 2018 Jan 31; 14(6). PMID: 29381418    Free PMC article.
Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.
David Taggart, Tereza Andreou, +7 authors, Mihaela Lorger.
Proc Natl Acad Sci U S A, 2018 Feb 02; 115(7). PMID: 29386395    Free PMC article.
Highly Cited.
Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies.
Danuta J Herzyk, Helen G Haggerty.
AAPS J, 2018 Feb 09; 20(2). PMID: 29417397
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.
Amanda J Oliver, Peter K H Lau, +4 authors, Clare Y Slaney.
Front Immunol, 2018 Feb 16; 9. PMID: 29445373    Free PMC article.
CAR-T cells: the long and winding road to solid tumors.
Maria Michela D'Aloia, Ilaria Grazia Zizzari, +2 authors, Maurizio Alimandi.
Cell Death Dis, 2018 Feb 17; 9(3). PMID: 29449531    Free PMC article.
Highly Cited. Review.
Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer.
Megan Morisada, Michael Chamberlin, Clint Allen.
Head Neck, 2018 Feb 21; 40(6). PMID: 29461655    Free PMC article.
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.
Xuexiang Du, Mingyue Liu, +8 authors, Pan Zheng.
Cell Res, 2018 Feb 22; 28(4). PMID: 29463898    Free PMC article.
Highly Cited.
Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells.
Gap Ryol Lee.
Mediators Inflamm, 2018 Feb 22; 2017. PMID: 29463952    Free PMC article.
Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis.
B L Adler, M K Pezhouh, +15 authors, R A Anders.
J Intern Med, 2018 Feb 22; 283(6). PMID: 29464806    Free PMC article.
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Xuexiang Du, Fei Tang, +14 authors, Yang Liu.
Cell Res, 2018 Feb 24; 28(4). PMID: 29472691    Free PMC article.
Highly Cited.
Checks and Balances in Autoimmune Vasculitis.
Rebeca Hid Cadena, Wayel H Abdulahad, +4 authors, Elisabeth Brouwer.
Front Immunol, 2018 Mar 10; 9. PMID: 29520282    Free PMC article.
FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.
Theresa L Whiteside.
Expert Opin Ther Targets, 2018 Mar 14; 22(4). PMID: 29532697    Free PMC article.
The Yin and Yang of regulatory T cells in immunotherapy.
Yan Li, James P Di Santo.
Oncotarget, 2018 Mar 16; 9(13). PMID: 29541377    Free PMC article.
Current status and perspectives in immunotherapy for metastatic melanoma.
Riccardo Marconcini, Francesco Spagnolo, +13 authors, Italian Melanoma Intergroup (IMI).
Oncotarget, 2018 Mar 20; 9(15). PMID: 29552325    Free PMC article.
Cancer vaccines: translation from mice to human clinical trials.
Hoyoung Maeng, Masaki Terabe, Jay A Berzofsky.
Curr Opin Immunol, 2018 Mar 20; 51. PMID: 29554495    Free PMC article.
Current Strategies to Enhance Anti-Tumour Immunity.
Katherine W Cook, Lindy G Durrant, Victoria A Brentville.
Biomedicines, 2018 Mar 24; 6(2). PMID: 29570634    Free PMC article.
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Frederick Arce Vargas, Andrew J S Furness, +32 authors, Sergio A Quezada.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576375    Free PMC article.
Highly Cited.
Anti-CTLA-4 therapy requires an Fc domain for efficacy.
Jessica R Ingram, Olga S Blomberg, +15 authors, Michael Dougan.
Proc Natl Acad Sci U S A, 2018 Mar 28; 115(15). PMID: 29581255    Free PMC article.
Highly Cited.
Harnessing and Optimizing the Interplay between Immunotherapy and Radiotherapy to Improve Survival Outcomes.
Kalpana Mujoo, Clayton R Hunt, +5 authors, Tej K Pandita.
Mol Cancer Res, 2018 Mar 30; 16(8). PMID: 29592896    Free PMC article.
Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy.
Jonathan Pol, Guido Kroemer.
Cell Res, 2018 Mar 30; 28(5). PMID: 29593340    Free PMC article.
Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.
Sandrine Niyongere, Andreas Saltos, Jhanelle E Gray.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593889    Free PMC article.
Targeting Macrophages in Cancer: From Bench to Bedside.
Ashleigh R Poh, Matthias Ernst.
Front Oncol, 2018 Mar 30; 8. PMID: 29594035    Free PMC article.
Highly Cited. Review.
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
Randi B Gombos, Ana Gonzalez, +24 authors, Nicholas S Wilson.
PLoS One, 2018 Apr 05; 13(4). PMID: 29617360    Free PMC article.
IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy.
Jianmin Zhu, Jin-Qing Liu, +11 authors, Xue-Feng Bai.
JCI Insight, 2018 Apr 06; 3(7). PMID: 29618655    Free PMC article.
Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.
Jeremy M Grenier, Stephen T Yeung, Kamal M Khanna.
Front Immunol, 2018 Apr 07; 9. PMID: 29623082    Free PMC article.
Macrophages: The Road Less Traveled, Changing Anticancer Therapy.
Jennifer L Guerriero.
Trends Mol Med, 2018 Apr 16; 24(5). PMID: 29655673    Free PMC article.
Highly Cited. Review.
An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides.
Laura L Eggink, Katherine F Roby, Robert Cote, J Kenneth Hoober.
J Immunother Cancer, 2018 Apr 19; 6(1). PMID: 29665849    Free PMC article.
Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors.
Luca Cassetta, Takanori Kitamura.
Front Cell Dev Biol, 2018 Apr 20; 6. PMID: 29670880    Free PMC article.
Highly Cited. Review.
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
Fei Tang, Xuexiang Du, +2 authors, Yang Liu.
Cell Biosci, 2018 May 02; 8. PMID: 29713453    Free PMC article.
Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.
Erika J Crosby, Junping Wei, +10 authors, Zachary C Hartman.
Oncoimmunology, 2018 May 04; 7(5). PMID: 29721371    Free PMC article.
Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity.
Marka R Crittenden, Lauren Zebertavage, +7 authors, Michael J Gough.
Sci Rep, 2018 May 05; 8(1). PMID: 29725089    Free PMC article.
Transcriptional characterization of immunological infiltrates and their relation with glioblastoma patients overall survival.
Mariana Brutschin Pereira, Luciana Rodrigues Carvalho Barros, +4 authors, Guido Lenz.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872555    Free PMC article.
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.
Elizabeth Ahern, Heidi Harjunpää, +4 authors, Mark J Smyth.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872559    Free PMC article.
Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Ee Lyn Lim, Fiorella M Cugliandolo, +3 authors, Klaus Okkenhaug.
JCI Insight, 2018 Jun 08; 3(11). PMID: 29875319    Free PMC article.
Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Jeremy D Waight, Dhan Chand, +14 authors, Nicholas S Wilson.
Cancer Cell, 2018 Jun 13; 33(6). PMID: 29894690    Free PMC article.
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.
David Wang, Jason Quiros, +12 authors, Michel DuPage.
Cell Rep, 2018 Jun 14; 23(11). PMID: 29898397    Free PMC article.
Highly Cited.
The promise and challenges of immune agonist antibody development in cancer.
Patrick A Mayes, Kenneth W Hance, Axel Hoos.
Nat Rev Drug Discov, 2018 Jun 16; 17(7). PMID: 29904196
Highly Cited. Review.
Aptamers: novelty tools for cancer biology.
Ricardo L Pereira, Isis C Nascimento, +4 authors, Henning Ulrich.
Oncotarget, 2018 Jun 22; 9(42). PMID: 29928493    Free PMC article.
Size-Dependent Segregation Controls Macrophage Phagocytosis of Antibody-Opsonized Targets.
Matthew H Bakalar, Aaron M Joffe, +3 authors, Daniel A Fletcher.
Cell, 2018 Jun 30; 174(1). PMID: 29958103    Free PMC article.
Highly Cited.
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Muhammad Umair Mushtaq, Athanasios Papadas, +4 authors, Fotis Asimakopoulos.
J Immunother Cancer, 2018 Jul 05; 6(1). PMID: 29970158    Free PMC article.
Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.
Lekh N Dahal, Chie-Yin Huang, +10 authors, Stephen A Beers.
J Immunol, 2018 Jul 13; 201(4). PMID: 29997125    Free PMC article.
Novel tumour antigens and the development of optimal vaccine design.
Victoria A Brentville, Suha Atabani, Katherine Cook, Lindy G Durrant.
Ther Adv Vaccines Immunother, 2018 Jul 13; 6(2). PMID: 29998219    Free PMC article.
Efficacy and immune activation of ipilimumab in early-stage lung cancer patients.
Shingo Noguchi, Kazuhiro Yatera.
J Thorac Dis, 2018 Jul 20; 10(Suppl 17). PMID: 30023087    Free PMC article.
Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts.
Christoph Goletz, Timo Lischke, +4 authors, Steffen Goletz.
Front Immunol, 2018 Aug 01; 9. PMID: 30061887    Free PMC article.
Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Abigail E Overacre-Delgoffe, Dario A A Vignali.
Cancer Immunol Res, 2018 Aug 03; 6(8). PMID: 30068755    Free PMC article.
Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors.
Yingming Zhu, Fen Zhao, Zhenxiang Li, Jinming Yu.
Cancer Manag Res, 2018 Aug 21; 10. PMID: 30122997    Free PMC article.
Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity.
Brett Schrand, Emily Clark, +5 authors, Eli Gilboa.
Nat Commun, 2018 Aug 24; 9(1). PMID: 30135425    Free PMC article.
Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance.
Young-Jun Park, Da-Sol Kuen, Yeonseok Chung.
Exp Mol Med, 2018 Aug 24; 50(8). PMID: 30135516    Free PMC article.
Highly Cited. Review.
Strategies for Predicting Response to Checkpoint Inhibitors.
Roberta Zappasodi, Jedd D Wolchok, Taha Merghoub.
Curr Hematol Malig Rep, 2018 Aug 31; 13(5). PMID: 30159703    Free PMC article.
Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Daniela Cornelia Lazăr, Mihaela Flavia Avram, +3 authors, Adrian Goldiș.
World J Gastroenterol, 2018 Sep 01; 24(32). PMID: 30166856    Free PMC article.
Highly Cited. Review.
Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.
Christine A Garcia, Alex El-Ali, +4 authors, Diwakar Davar.
J Immunother Cancer, 2018 Sep 02; 6(1). PMID: 30170622    Free PMC article.
A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Prabhakaran Kumar, Palash Bhattacharya, Bellur S Prabhakar.
J Autoimmun, 2018 Sep 04; 95. PMID: 30174217    Free PMC article.
Autochthonous murine models for the study of smoker and never-smoker associated lung cancers.
Esra A Akbay, James Kim.
Transl Lung Cancer Res, 2018 Sep 19; 7(4). PMID: 30225211    Free PMC article.
Not All Immune Checkpoints Are Created Equal.
Annika De Sousa Linhares, Judith Leitner, Katharina Grabmeier-Pfistershammer, Peter Steinberger.
Front Immunol, 2018 Sep 21; 9. PMID: 30233564    Free PMC article.
Highly Cited. Review.
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Nayoung Kim, Hun Sik Kim.
Front Immunol, 2018 Sep 27; 9. PMID: 30250471    Free PMC article.
Highly Cited. Review.
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
David A Knorr, Rony Dahan, Jeffrey V Ravetch.
Proc Natl Acad Sci U S A, 2018 Oct 10; 115(43). PMID: 30297432    Free PMC article.
Regulatory T cells in the treatment of disease.
Amir Sharabi, Maria G Tsokos, +3 authors, George C Tsokos.
Nat Rev Drug Discov, 2018 Oct 13; 17(11). PMID: 30310234
Highly Cited. Review.
On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies.
Frank J Ward, Lekh N Dahal, Rasha Abu-Eid.
Front Immunol, 2018 Oct 16; 9. PMID: 30319637    Free PMC article.
Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types.
Angela M Magnuson, Evgeny Kiner, +8 authors, Christophe Benoist.
Proc Natl Acad Sci U S A, 2018 Oct 24; 115(45). PMID: 30348759    Free PMC article.
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.
Samantha L Bucktrout, Jeffrey A Bluestone, Fred Ramsdell.
Genome Med, 2018 Nov 01; 10(1). PMID: 30376867    Free PMC article.
Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma.
H Degroote, A Van Dierendonck, +2 authors, L Devisscher.
J Immunol Res, 2018 Nov 10; 2018. PMID: 30410942    Free PMC article.
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
Chien-Chun Steven Pai, John T Huang, +24 authors, Lawrence Fong.
Immunity, 2019 Feb 10; 50(2). PMID: 30737146    Free PMC article.
Highly Cited.
Rheumatic complications in cancer patients treated with immune checkpoint inhibitors.
Kyung-Ann Lee, Hae-Rim Kim, So Young Yoon.
Korean J Intern Med, 2019 Apr 25; 34(6). PMID: 31014065    Free PMC article.
Characterization and Comparison of GITR Expression in Solid Tumors.
Luis Vence, Samantha L Bucktrout, +17 authors, Padmanee Sharma.
Clin Cancer Res, 2019 Jul 31; 25(21). PMID: 31358539    Free PMC article.
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.
Joseph L Benci, Lexus R Johnson, +14 authors, Andy J Minn.
Cell, 2019 Aug 10; 178(4). PMID: 31398344    Free PMC article.
Highly Cited.
ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity.
Mario Martínez Soldevilla, Helena Villanueva, +10 authors, Fernando Pastor.
Mol Ther, 2019 Aug 14; 27(11). PMID: 31405808    Free PMC article.
Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression.
Chloé Laplagne, Marcin Domagala, +7 authors, Mary Poupot.
Int J Mol Sci, 2019 Sep 25; 20(19). PMID: 31547627    Free PMC article.
Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
JanWillem Duitman, Tom van den Ende, C Arnold Spek.
J Clin Med, 2019 Sep 29; 8(10). PMID: 31561518    Free PMC article.
CTLA-4 Immunohistochemistry and Quantitative Image Analysis for Profiling of Human Cancers.
Charles Brown, Farzad Sekhavati, +4 authors, Keith E Steele.
J Histochem Cytochem, 2019 Oct 15; 67(12). PMID: 31609157    Free PMC article.
NK Cell-Fc Receptors Advance Tumor Immunotherapy.
Emilio Sanseviero.
J Clin Med, 2019 Oct 17; 8(10). PMID: 31614774    Free PMC article.
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Spencer C Wei, Nana-Ama A S Anang, +8 authors, James P Allison.
Proc Natl Acad Sci U S A, 2019 Oct 23; 116(45). PMID: 31636208    Free PMC article.
T Regulatory Cells and Priming the Suppressive Tumor Microenvironment.
Christina M Paluskievicz, Xuefang Cao, +3 authors, Jonathan S Bromberg.
Front Immunol, 2019 Nov 05; 10. PMID: 31681327    Free PMC article.
Expression of CD39 Is Correlated With HIV DNA Levels in Naïve Tregs in Chronically Infected ART Naïve Patients.
Jin-Wen Song, Hui-Huang Huang, +7 authors, Yan-Mei Jiao.
Front Immunol, 2019 Nov 05; 10. PMID: 31681335    Free PMC article.
Foxp3 Post-translational Modifications and Treg Suppressive Activity.
Guoping Deng, Xiaomin Song, +3 authors, Mark I Greene.
Front Immunol, 2019 Nov 05; 10. PMID: 31681337    Free PMC article.
Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy.
Sunkuk Kwon, Fred Christian Velasquez, +7 authors, Eva M Sevick-Muraca.
Theranostics, 2019 Nov 23; 9(26). PMID: 31754400    Free PMC article.
Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Sophia C Weinmann, David S Pisetsky.
Rheumatology (Oxford), 2019 Dec 10; 58(Suppl 7). PMID: 31816080    Free PMC article.
Allies or Enemies-The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment.
Lisa Haas, Anna C Obenauf.
Front Immunol, 2019 Dec 19; 10. PMID: 31849950    Free PMC article.
Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.
David A Knorr, Aaron D Goldberg, Eytan M Stein, Martin S Tallman.
Leuk Lymphoma, 2019 Jul 25; 60(14). PMID: 31335250    Free PMC article.
The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies.
Kroopa Joshi, Benjamin M Chain, Karl S Peggs, Sergio A Quezada.
Cold Spring Harb Perspect Med, 2017 Jun 21; 8(1). PMID: 28630228    Free PMC article.
High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
Heather L MacGregor, Azin Sayad, +9 authors, Pamela S Ohashi.
J Immunother Cancer, 2020 Jan 02; 7(1). PMID: 31892360    Free PMC article.
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.
Yan Zhang, Xuexiang Du, +9 authors, Yang Liu.
Cell Res, 2019 Jul 04; 29(8). PMID: 31267017    Free PMC article.
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells.
Kazushige Yoshida, Masanori Okamoto, +13 authors, Naoto Saito.
BMC Cancer, 2020 Jan 10; 20(1). PMID: 31914969    Free PMC article.
Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Emilio Sanseviero, Erin M O'Brien, +16 authors, Erica L Stone.
Cancer Immunol Res, 2019 Jun 27; 7(8). PMID: 31239316    Free PMC article.
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Barbara Melosky, Rosalyn Juergens, +5 authors, Quincy Chu.
Oncologist, 2019 May 30; 25(1). PMID: 31138727    Free PMC article.
Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells.
Cornelia Hutmacher, Nicolás Gonzalo Núñez, +2 authors, Dario Neri.
Cancer Immunol Res, 2019 Feb 21; 7(4). PMID: 30782667    Free PMC article.
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.
Shaheen Khan, David E Gerber.
Semin Cancer Biol, 2019 Jul 23; 64. PMID: 31330185    Free PMC article.
Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Fa-Peng Zhang, Yi-Pei Huang, +4 authors, Chao Liu.
World J Gastroenterol, 2020 Jan 24; 26(2). PMID: 31969776    Free PMC article.
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors.
Nicholas Gravbrot, Kacy Gilbert-Gard, +4 authors, Srinath Sundararajan.
Antibodies (Basel), 2019 Oct 24; 8(4). PMID: 31640266    Free PMC article.
Targeted Delivery of TNF Potentiates the Antibody-Dependent Cell-Mediated Cytotoxicity of an Anti-Melanoma Immunoglobulin.
Patrizia Murer, Jonathan D Kiefer, +4 authors, Dario Neri.
J Invest Dermatol, 2018 Dec 14; 139(6). PMID: 30543899    Free PMC article.
IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development.
Amy Li, Rebecca H Herbst, +15 authors, Tyler Jacks.
Cell Rep, 2019 Dec 05; 29(10). PMID: 31801068    Free PMC article.
Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance.
Tijana Martinov, Brian T Fife.
Ann N Y Acad Sci, 2019 Apr 27; 1461(1). PMID: 31025378    Free PMC article.
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Meenu Sharma, Hiep Khong, +28 authors, Willem W Overwijk.
Nat Commun, 2020 Feb 02; 11(1). PMID: 32005826    Free PMC article.
Immunotherapies for pediatric cancer: current landscape and future perspectives.
Brian Hutzen, Siddhi Nath Paudel, +3 authors, Timothy P Cripe.
Cancer Metastasis Rev, 2019 Dec 13; 38(4). PMID: 31828566    Free PMC article.
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.
Haiping Wang, Fabien Franco, +17 authors, Ping-Chih Ho.
Nat Immunol, 2020 Feb 19; 21(3). PMID: 32066953    Free PMC article.
Effect of pembrolizumab on CD4+ CD25+ , CD4+ LAP+ and CD4+ TIM-3+ T cell subsets.
S M Toor, V Sasidharan Nair, G Pfister, E Elkord.
Clin Exp Immunol, 2019 Jan 30; 196(3). PMID: 30693485    Free PMC article.
Structure and Optimization of Checkpoint Inhibitors.
Sarah L Picardo, Jeffrey Doi, Aaron R Hansen.
Cancers (Basel), 2019 Dec 28; 12(1). PMID: 31877721    Free PMC article.
A functional antibody cross-reactive to both human and murine cytotoxic T-lymphocyte-associated protein 4 via binding to an N-glycosylation epitope.
Dong Li, Jing Li, Huanyu Chu, Zhuozhi Wang.
MAbs, 2020 Feb 15; 12(1). PMID: 32054416    Free PMC article.
NK Cell-Based Immune Checkpoint Inhibition.
Muhammad Khan, Sumbal Arooj, Hua Wang.
Front Immunol, 2020 Mar 03; 11. PMID: 32117298    Free PMC article.
TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion.
Naveen Sharma, Jean Vacher, James P Allison.
Proc Natl Acad Sci U S A, 2019 May 12; 116(21). PMID: 31076558    Free PMC article.
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.
Mohammad Rashidian, Martin W LaFleur, +13 authors, Hidde L Ploegh.
Proc Natl Acad Sci U S A, 2019 Aug 04; 116(34). PMID: 31375632    Free PMC article.
Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations.
Masashi Fujita, Rui Yamaguchi, +18 authors, Hidewaki Nakagawa.
EBioMedicine, 2020 Mar 01; 53. PMID: 32113157    Free PMC article.
Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
Gemlyn George, Laura Schmidt, +2 authors, Deepak Kilari.
J Immunother Cancer, 2020 Mar 03; 8(1). PMID: 32114501    Free PMC article.
CTLA-4: a moving target in immunotherapy.
Behzad Rowshanravan, Neil Halliday, David M Sansom.
Blood, 2017 Nov 10; 131(1). PMID: 29118008    Free PMC article.
Highly Cited. Review.
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.
Ariel E Marciscano, Ali Ghasemzadeh, +18 authors, Charles G Drake.
Clin Cancer Res, 2018 Jun 15; 24(20). PMID: 29898992    Free PMC article.
Acquired resistance to cancer immunotherapy.
Arianna Draghi, Christopher Aled Chamberlain, Andrew Furness, Marco Donia.
Semin Immunopathol, 2018 Jul 04; 41(1). PMID: 29968044
Therapeutic cancer vaccine: building the future from lessons of the past.
T Tran, C Blanc, +3 authors, Eric Tartour.
Semin Immunopathol, 2018 Jul 07; 41(1). PMID: 29978248
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.
Rachael M Zemek, Wee Loong Chin, +3 authors, W Joost Lesterhuis.
Front Immunol, 2020 Mar 07; 11. PMID: 32133005    Free PMC article.
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.
Anu Sharma, Sumit K Subudhi, +6 authors, Padmanee Sharma.
Clin Cancer Res, 2018 Jul 29; 25(4). PMID: 30054281    Free PMC article.
Highly Cited.
Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers.
Stephanie Dorta-Estremera, Renee L Chin, +7 authors, K Jagannadha Sastry.
Cancer Res, 2018 Jul 29; 78(18). PMID: 30054333    Free PMC article.
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.
Matthew M Gubin, Ekaterina Esaulova, +16 authors, Maxim N Artyomov.
Cell, 2018 Oct 23; 175(4). PMID: 30343900    Free PMC article.
Highly Cited.
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Chien-Chun Steven Pai, Donald M Simons, +22 authors, Lawrence Fong.
J Clin Invest, 2018 Dec 12; 129(1). PMID: 30530991    Free PMC article.
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Danbee Ha, Atsushi Tanaka, +10 authors, Shimon Sakaguchi.
Proc Natl Acad Sci U S A, 2018 Dec 28; 116(2). PMID: 30587582    Free PMC article.
Delivery technologies for cancer immunotherapy.
Rachel S Riley, Carl H June, Robert Langer, Michael J Mitchell.
Nat Rev Drug Discov, 2019 Jan 10; 18(3). PMID: 30622344    Free PMC article.
Highly Cited. Review.
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.
Daisuke Muraoka, Naohiro Seo, +17 authors, Hiroshi Shiku.
J Clin Invest, 2019 Jan 11; 129(3). PMID: 30628894    Free PMC article.
Immune checkpoint inhibitors.
Enfu Hui.
J Cell Biol, 2019 Feb 15; 218(3). PMID: 30760493    Free PMC article.
Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity.
Masanori Onda, Kazuto Kobayashi, Ira Pastan.
Proc Natl Acad Sci U S A, 2019 Feb 15; 116(10). PMID: 30760587    Free PMC article.
Genomic correlates of response to immune checkpoint blockade.
Tanya E Keenan, Kelly P Burke, Eliezer M Van Allen.
Nat Med, 2019 Mar 08; 25(3). PMID: 30842677    Free PMC article.
Highly Cited. Review.
Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.
Priscilla Do, Kyle A Beckwith, +9 authors, John C Byrd.
J Immunol, 2019 Mar 27; 202(9). PMID: 30910862    Free PMC article.
Targeted antibody and cytokine cancer immunotherapies through collagen affinity.
Jun Ishihara, Ako Ishihara, +15 authors, Jeffrey A Hubbell.
Sci Transl Med, 2019 Apr 12; 11(487). PMID: 30971453    Free PMC article.
Highly Cited.
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Anne Månsson Kvarnhammar, Niina Veitonmäki, +16 authors, Peter Ellmark.
J Immunother Cancer, 2019 Apr 13; 7(1). PMID: 30975201    Free PMC article.
Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Huijuan Song, Pengxiang Yang, +3 authors, Weiwei Wang.
Theranostics, 2019 Jun 01; 9(8). PMID: 31149045    Free PMC article.
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response.
Anu Sharma, Sumit K Subudhi, +5 authors, Padmanee Sharma.
Clin Cancer Res, 2019 Jun 05; 25(11). PMID: 31160495    Free PMC article.
Regulatory T cells in cancer: where are we now?
Awen Gallimore, Sergio A Quezada, Rahul Roychoudhuri.
Immunology, 2019 Jun 22; 157(3). PMID: 31225653    Free PMC article.
Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway.
Todd Bartkowiak, Ashvin R Jaiswal, +8 authors, Michael A Curran.
Clin Cancer Res, 2018 Jan 06; 24(5). PMID: 29301830    Free PMC article.
Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients.
Jochen Greiner, Marlies Götz, +2 authors, Verena Wais.
J Clin Med, 2019 Dec 28; 9(1). PMID: 31878060    Free PMC article.
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.
Kei Kunimasa, Taichiro Goto.
Int J Mol Sci, 2020 Jan 23; 21(2). PMID: 31963413    Free PMC article.
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy.
Jung-Ho Kim, Beom Seok Kim, Sang-Kyou Lee.
Immune Netw, 2020 Mar 12; 20(1). PMID: 32158592    Free PMC article.
Mechanisms of human FoxP3+ Treg cell development and function in health and disease.
M Attias, T Al-Aubodah, C A Piccirillo.
Clin Exp Immunol, 2019 Mar 14; 197(1). PMID: 30864147    Free PMC article.
The multifaceted Foxp3fgfp allele enhances spontaneous and therapeutic immune surveillance of cancer in mice.
José Almeida-Santos, Marie-Louise Bergman, +3 authors, Jocelyne Demengeot.
Eur J Immunol, 2019 Nov 16; 50(3). PMID: 31729760    Free PMC article.
Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies.
Peng Zhang, Xinxin Xiong, +8 authors, Pan Zheng.
Cancers (Basel), 2020 Jan 30; 12(2). PMID: 31991588    Free PMC article.
Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
Michael Dougan.
Curr Gastroenterol Rep, 2020 Mar 19; 22(4). PMID: 32185493
Determinants of Resistance to Checkpoint Inhibitors.
Linda Tran, Dan Theodorescu.
Int J Mol Sci, 2020 Mar 01; 21(5). PMID: 32111080    Free PMC article.
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.
Afsheen Raza, Maysaloun Merhi, +4 authors, Said Dermime.
J Transl Med, 2020 Mar 30; 18(1). PMID: 32220256    Free PMC article.
CoRESTed development of regulatory T cells.
Luisa Morales-Nebreda, Kathryn A Helmin, Benjamin D Singer.
J Clin Invest, 2020 Mar 04; 130(4). PMID: 32125289    Free PMC article.
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology.
Paul David, Malgorzata Drabczyk-Pluta, +24 authors, Gennadiy Zelinskyy.
PLoS Pathog, 2020 Apr 01; 16(3). PMID: 32226027    Free PMC article.
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity.
Alexandra Schnell, Lloyd Bod, Asaf Madi, Vijay K Kuchroo.
Cell Res, 2020 Jan 25; 30(4). PMID: 31974523    Free PMC article.
Modulating inflammation for cancer therapy.
Birgit Ritter, Florian R Greten.
J Exp Med, 2019 Apr 27; 216(6). PMID: 31023715    Free PMC article.
Highly Cited. Review.
Development of immune checkpoint therapy for cancer.
Jill M Fritz, Michael J Lenardo.
J Exp Med, 2019 May 10; 216(6). PMID: 31068379    Free PMC article.
Highly Cited. Review.
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents.
Paola Ciciola, Priscilla Cascetta, +2 authors, Roberto Bianco.
J Clin Med, 2020 Mar 07; 9(3). PMID: 32138216    Free PMC article.
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
Ingrid Teige, Linda Mårtensson, Björn L Frendéus.
Front Immunol, 2019 Apr 02; 10. PMID: 30930905    Free PMC article.
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
Duaa O Khair, Heather J Bax, +22 authors, Sophia N Karagiannis.
Front Immunol, 2019 Apr 04; 10. PMID: 30941125    Free PMC article.
Highly Cited. Review.
ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy.
Ya-Ru Miao, Qiong Zhang, +4 authors, An-Yuan Guo.
Adv Sci (Weinh), 2020 Apr 11; 7(7). PMID: 32274301    Free PMC article.
FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
Xin Chen, Xiaomin Song, Kang Li, Tong Zhang.
Front Immunol, 2019 Mar 14; 10. PMID: 30863404    Free PMC article.
Highly Cited. Review.
Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges.
Ilenia Pacella, Silvia Piconese.
Front Immunol, 2019 Sep 12; 10. PMID: 31507585    Free PMC article.
Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Antonio Marchini, Laurent Daeffler, +2 authors, Jean Rommelaere.
Front Immunol, 2019 Aug 24; 10. PMID: 31440242    Free PMC article.
Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Alexander H Morrison, Mark S Diamond, +2 authors, Robert H Vonderheide.
Proc Natl Acad Sci U S A, 2020 Mar 28; 117(14). PMID: 32213589    Free PMC article.
Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Yoshihiro Ohue, Hiroyoshi Nishikawa.
Cancer Sci, 2019 May 19; 110(7). PMID: 31102428    Free PMC article.
Highly Cited. Review.
T Cell Dysfunction in Cancer Immunity and Immunotherapy.
Anliang Xia, Yan Zhang, +2 authors, Xiao-Jie Lu.
Front Immunol, 2019 Aug 06; 10. PMID: 31379886    Free PMC article.
Highly Cited. Review.
Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.
Vera Petrova, Ihor Arkhypov, +4 authors, Viktor Umansky.
Int J Mol Sci, 2020 Apr 03; 21(7). PMID: 32235439    Free PMC article.
Bispecific Antibodies in the Treatment of Hematologic Malignancies.
Johannes Duell, Philip E Lammers, +4 authors, Saar Gill.
Clin Pharmacol Ther, 2019 Feb 17; 106(4). PMID: 30770546    Free PMC article.
IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses.
Qiuxia Qu, Zhiwei Zhai, +3 authors, Binfeng Lu.
Front Immunol, 2020 May 01; 11. PMID: 32351508    Free PMC article.
Current issues and perspectives in PD-1 blockade cancer immunotherapy.
Kenji Chamoto, Ryusuke Hatae, Tasuku Honjo.
Int J Clin Oncol, 2020 Jan 05; 25(5). PMID: 31900651    Free PMC article.
Targeting T cell activation in immuno-oncology.
S D Saibil, P S Ohashi.
Curr Oncol, 2020 May 06; 27(Suppl 2). PMID: 32368179    Free PMC article.
Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways.
Polina Weitzenfeld, Stylianos Bournazos, Jeffrey V Ravetch.
J Clin Invest, 2019 Aug 20; 129(9). PMID: 31424423    Free PMC article.
Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.
Yang Liu, Pan Zheng.
Trends Pharmacol Sci, 2019 Dec 15; 41(1). PMID: 31836191    Free PMC article.
Inducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer.
Mengxiao Xie, Jia Wei, Jian Xu.
Front Immunol, 2020 May 20; 11. PMID: 32425930    Free PMC article.
Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis.
Yiding Li, Zhiming Wang, +16 authors, Lifan Xu.
Front Immunol, 2020 Jun 02; 11. PMID: 32477338    Free PMC article.
The future of cancer immunotherapy: microenvironment-targeting combinations.
Yonina R Murciano-Goroff, Allison Betof Warner, Jedd D Wolchok.
Cell Res, 2020 May 30; 30(6). PMID: 32467593    Free PMC article.
Plasma Cells in the Melanoma Tumor Microenvironment-Mechanistic Roles for IgA.
Rakesh Verma, Lalit Kumar.
Front Immunol, 2020 Jun 26; 11. PMID: 32582154    Free PMC article.
Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.
Amblessed E Onuma, Hongji Zhang, +3 authors, Allan Tsung.
Gene Expr, 2020 Apr 29; 20(1). PMID: 32340652    Free PMC article.
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.
Josée Golay, Alain E Andrea.
Antibodies (Basel), 2020 May 24; 9(2). PMID: 32443877    Free PMC article.
A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.
Joseph M Tuscano, Emanual Maverakis, +10 authors, Edward M Newman.
Clin Cancer Res, 2019 Sep 05; 25(23). PMID: 31481504    Free PMC article.
The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy.
Christiana M Neophytou, Chryso Pierides, +3 authors, Panagiotis Papageorgis.
Front Oncol, 2020 Jul 14; 10. PMID: 32656079    Free PMC article.
PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond.
Yasumasa Ishida.
Cells, 2020 Jun 05; 9(6). PMID: 32492969    Free PMC article.
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.
Mesude Bicak, Katharina Lückerath, +15 authors, David Ulmert.
Proc Natl Acad Sci U S A, 2020 Jun 14; 117(26). PMID: 32532924    Free PMC article.
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
Manuela Terranova-Barberio, Nela Pawlowska, +10 authors, Pamela N Munster.
Nat Commun, 2020 Jul 19; 11(1). PMID: 32681091    Free PMC article.
Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells.
Anna Śledzińska, Maria Vila de Mucha, +19 authors, Sergio A Quezada.
Immunity, 2020 Jan 12; 52(1). PMID: 31924474    Free PMC article.
A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth.
María Alejandra Gleisner, Cristián Pereda, +9 authors, Flavio Salazar-Onfray.
J Immunother Cancer, 2020 Jul 22; 8(2). PMID: 32690772    Free PMC article.
Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors.
Diwakar Davar, Hassane M Zarour.
Methods Mol Biol, 2019 Sep 11; 2055. PMID: 31502146    Free PMC article.
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.
Adrienne M Luoma, Shengbao Suo, +13 authors, Kai W Wucherpfennig.
Cell, 2020 Jul 01; 182(3). PMID: 32603654    Free PMC article.
Immunotherapies and Combination Strategies for Immuno-Oncology.
Cody Barbari, Tyler Fontaine, +4 authors, Rahul R Deshmukh.
Int J Mol Sci, 2020 Jul 19; 21(14). PMID: 32679922    Free PMC article.
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.
Yuanyuan Zhang, Zemin Zhang.
Cell Mol Immunol, 2020 Jul 03; 17(8). PMID: 32612154    Free PMC article.
A Review of T-Cell Related Therapy for Osteosarcoma.
Kazushige Yoshida, Masanori Okamoto, +2 authors, Naoto Saito.
Int J Mol Sci, 2020 Jul 16; 21(14). PMID: 32664248    Free PMC article.
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Luis Felipe Campesato, Sadna Budhu, +15 authors, Jedd D Wolchok.
Nat Commun, 2020 Aug 13; 11(1). PMID: 32782249    Free PMC article.
Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy.
Reza Alimohammadi, Razieh Alibeigi, +4 authors, Seyed Amir Jalali.
Int J Nanomedicine, 2020 Aug 18; 15. PMID: 32801691    Free PMC article.
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review.
Naoko Okura, Mai Asano, +6 authors, Koichi Takayama.
J Clin Med, 2020 Jul 03; 9(7). PMID: 32610470    Free PMC article.
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy.
Lukas Amon, Lukas Hatscher, +2 authors, Christian H K Lehmann.
Pharmaceutics, 2020 Jul 18; 12(7). PMID: 32674488    Free PMC article.
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies.
Shin Foong Ngiow, Arabella Young.
Front Immunol, 2020 Aug 28; 11. PMID: 32849557    Free PMC article.
Scientifically based combination therapies with immuno-oncology checkpoint inhibitors.
Hui Yi Chew, Riccardo Dolcetti, Fiona Simpson.
Br J Clin Pharmacol, 2020 May 07; 86(9). PMID: 32372470    Free PMC article.
Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy.
Brendan L Mangan, Renee K McAlister, +4 authors, Elizabeth J Phillips.
Br J Clin Pharmacol, 2020 Jun 17; 86(9). PMID: 32543711    Free PMC article.
The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019.
Paolo A Ascierto, Carlo Bifulco, +12 authors, Igor Puzanov.
J Immunother Cancer, 2020 Aug 28; 8(2). PMID: 32843491    Free PMC article.
Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
Ali Shamseddine, Youssef H Zeidan, +22 authors, Fady Geara.
BMC Cancer, 2020 Sep 03; 20(1). PMID: 32873251    Free PMC article.
Combinatorial approach to cancer immunotherapy: strength in numbers.
Anna E Vilgelm, Douglas B Johnson, Ann Richmond.
J Leukoc Biol, 2016 Jun 04; 100(2). PMID: 27256570    Free PMC article.
Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses.
Amanda J Oliver, Phillip K Darcy, Michael H Kershaw, Clare Y Slaney.
J Thorac Dis, 2020 Sep 19; 12(8). PMID: 32944364    Free PMC article.
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.
Robert L Ferris, Heinz-Josef Lenz, +5 authors, Gerard Milano.
Cancer Treat Rev, 2017 Dec 11; 63. PMID: 29223828    Free PMC article.
Human regulatory T cells (Treg) and their response to cancer.
Theresa L Whiteside.
Expert Rev Precis Med Drug Dev, 2019 Jan 01; 4(4). PMID: 32953989    Free PMC article.
Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?
Purushottam Lamichhane, Neha P Amin, Manuj Agarwal, Narottam Lamichhane.
Medicines (Basel), 2018 Oct 27; 5(4). PMID: 30360504    Free PMC article.
Radiotherapy as a New Player in Immuno-Oncology.
Shang-Jui Wang, Bruce Haffty.
Cancers (Basel), 2018 Dec 19; 10(12). PMID: 30558196    Free PMC article.
Tregs, Helios and tumor immunity: the sun has not yet risen.
Angela M Thornton, Ethan M Shevach.
Transl Cancer Res, 2016 Oct 01; 5(Suppl 4). PMID: 30637198    Free PMC article.
On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy.
Benjamin Y Kong, Holly Bolton, +3 authors, Georgina J Clark.
Front Oncol, 2019 Feb 23; 9. PMID: 30788290    Free PMC article.
Turning the Tide Against Regulatory T Cells.
SeongJun Han, Aras Toker, Zhe Qi Liu, Pamela S Ohashi.
Front Oncol, 2019 May 07; 9. PMID: 31058083    Free PMC article.
Macrophages in Colorectal Cancer Liver Metastases.
Nina Cortese, Cristiana Soldani, +4 authors, Matteo Donadon.
Cancers (Basel), 2019 May 10; 11(5). PMID: 31067629    Free PMC article.
A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system.
Aude Burlion, Rodrigo N Ramos, +7 authors, Gilles Marodon.
Oncoimmunology, 2019 May 31; 8(7). PMID: 31143518    Free PMC article.
The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response.
Jihane Boustani, Mathieu Grapin, +2 authors, Céline Mirjolet.
Cancers (Basel), 2019 Jun 23; 11(6). PMID: 31226866    Free PMC article.
CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
Francesca Zammarchi, Karin Havenith, +3 authors, Patrick H van Berkel.
J Immunother Cancer, 2020 Sep 12; 8(2). PMID: 32912922    Free PMC article.
ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.
Amanda Hanson, Kutlu Elpek, +16 authors, Christopher J Harvey.
PLoS One, 2020 Sep 25; 15(9). PMID: 32970735    Free PMC article.
Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy.
Michael Dougan.
Cancer Immunol Res, 2020 Oct 03; 8(10). PMID: 33004412    Free PMC article.
The Crosstalk between Microbiome and Immune Response in Gastric Cancer.
Rihab Nasr, Ali Shamseddine, +2 authors, Sally Temraz.
Int J Mol Sci, 2020 Sep 13; 21(18). PMID: 32916853    Free PMC article.
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade.
Weilei Hu, Guosheng Wang, +2 authors, Ming You.
iScience, 2020 Oct 22; 23(10). PMID: 33083746    Free PMC article.
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance.
Catherine L Tan, Juhi R Kuchroo, +15 authors, Arlene H Sharpe.
J Exp Med, 2020 Oct 13; 218(1). PMID: 33045061    Free PMC article.
Computational Verification of Large Logical Models-Application to the Prediction of T Cell Response to Checkpoint Inhibitors.
Céline Hernandez, Morgane Thomas-Chollier, Aurélien Naldi, Denis Thieffry.
Front Physiol, 2020 Oct 27; 11. PMID: 33101049    Free PMC article.
Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer.
Fang-Fei Qian, Bao-Hui Han.
Chin Med J (Engl), 2020 Sep 25; 133(20). PMID: 32969861    Free PMC article.
Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions.
Guoming Zeng, Libo Jin, +9 authors, Da Sun.
Cancer Manag Res, 2020 Oct 30; 12. PMID: 33116895    Free PMC article.
Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation.
Jin-Hwan Han, Mingmei Cai, +9 authors, Sybil M Genther Williams.
Front Immunol, 2020 Oct 30; 11. PMID: 33117369    Free PMC article.
Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
Emmanuel Donnadieu, Loïc Dupré, Lia Gonçalves Pinho, Vinicius Cotta-de-Almeida.
J Leukoc Biol, 2020 Jul 04; 108(4). PMID: 32620049    Free PMC article.
Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Melissa Gamat-Huber, Donghwan Jeon, +7 authors, Douglas G McNeel.
Cancers (Basel), 2020 Oct 04; 12(10). PMID: 33008010    Free PMC article.
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy.
Italia Falcone, Fabiana Conciatori, +4 authors, Michele Milella.
Cancers (Basel), 2020 Oct 11; 12(10). PMID: 33036192    Free PMC article.
Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.
Vanessa Gauttier, Sabrina Pengam, +40 authors, Nicolas Poirier.
J Clin Invest, 2020 Oct 20; 130(11). PMID: 33074246    Free PMC article.
Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy.
Lujun Chen, Runzi Sun, +9 authors, Binfeng Lu.
Cancer Immunol Res, 2020 Sep 13; 8(11). PMID: 32917659    Free PMC article.
Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions.
David Bauché, Smita Mauze, +11 authors, Drake Laface.
J Immunother Cancer, 2020 Nov 01; 8(2). PMID: 33127658    Free PMC article.
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Negar Hosseinkhani, Afshin Derakhshani, +9 authors, Behzad Baradaran.
Int J Mol Sci, 2020 Nov 11; 21(21). PMID: 33167514    Free PMC article.
Systematic Profiling of Immune Risk Model to Predict Survival and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.
Xingyu Liu, Jiarui Chen, +7 authors, Conghua Xie.
Front Genet, 2020 Nov 17; 11. PMID: 33193693    Free PMC article.
The Resistance Mechanisms of Lung Cancer Immunotherapy.
Fen Wang, Shubin Wang, Qing Zhou.
Front Oncol, 2020 Nov 17; 10. PMID: 33194652    Free PMC article.
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors.
Maddalena Centanni, Dirk Jan A R Moes, +2 authors, J G Coen van Hasselt.
Clin Pharmacokinet, 2019 Mar 01; 58(7). PMID: 30815848    Free PMC article.
Highly Cited. Review.
Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers.
Natasha A Jain, Songzhu Zhao, +4 authors, Dwight H Owen.
Cancer Manag Res, 2020 Nov 26; 12. PMID: 33235503    Free PMC article.
Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting?
Pierre Stéphan, Raphaëlle Lautraite, Allison Voisin, Yenkel Grinberg-Bleyer.
Cancers (Basel), 2020 Nov 05; 12(11). PMID: 33143070    Free PMC article.
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma.
Elena Shklovskaya, Jenny H Lee, +12 authors, Helen Rizos.
Cancers (Basel), 2020 Nov 19; 12(11). PMID: 33202676    Free PMC article.
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Caroline Jochems, Jo A Tucker, +6 authors, Jeffrey Schlom.
Cancer Immunol Immunother, 2014 Feb 12; 63(4). PMID: 24514956    Free PMC article.
The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients.
Richard P Tobin, Dana Davis, Kimberly R Jordan, Martin D McCarter.
J Leukoc Biol, 2017 Feb 10; 102(2). PMID: 28179538    Free PMC article.
Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma.
J M Moskovitz, R L Ferris.
J Dent Res, 2018 Mar 01; 97(6). PMID: 29489423    Free PMC article.
Mechanisms of Resistance to Immune Checkpoint Blockade.
David Liu, Russell W Jenkins, Ryan J Sullivan.
Am J Clin Dermatol, 2018 Sep 28; 20(1). PMID: 30259383    Free PMC article.
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.
Miguel F Sanmamed, Lieping Chen.
Cell, 2018 Oct 06; 175(2). PMID: 30290139    Free PMC article.
Highly Cited. Review.
How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?
Yang Liu, Pan Zheng.
Trends Immunol, 2018 Dec 01; 39(12). PMID: 30497614    Free PMC article.
Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases.
Zhen Xiang, Yingyan Yu.
Front Med, 2019 Jan 20; 13(1). PMID: 30659409
RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
Simon Heidegger, Diana Kreppel, +10 authors, Hendrik Poeck.
EBioMedicine, 2019 Mar 11; 41. PMID: 30852164    Free PMC article.
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma.
Junyu Long, Anqiang Wang, +6 authors, Haitao Zhao.
EBioMedicine, 2019 Mar 20; 42. PMID: 30885723    Free PMC article.
Highly Cited.
<Editors' Choice> Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
Vitaly Kochin, Hiroyoshi Nishikawa.
Nagoya J Med Sci, 2019 Apr 10; 81(1). PMID: 30962651    Free PMC article.
CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro.
Sandra Rosskopf, Judith Leitner, Gerhard J Zlabinger, Peter Steinberger.
Cancer Immunol Immunother, 2019 Jul 25; 68(8). PMID: 31332464    Free PMC article.
Maintenance DNA methylation is essential for regulatory T cell development and stability of suppressive function.
Kathryn A Helmin, Luisa Morales-Nebreda, +9 authors, Benjamin D Singer.
J Clin Invest, 2020 Sep 09; 130(12). PMID: 32897881    Free PMC article.
Overcoming Immune Evasion in Melanoma.
Kevinn Eddy, Suzie Chen.
Int J Mol Sci, 2020 Dec 02; 21(23). PMID: 33256089    Free PMC article.
Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody.
Han Gao, Haiyan Cai, +7 authors, Aiwu Zhou.
Cell Discov, 2020 Dec 11; 6(1). PMID: 33298884    Free PMC article.
The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review.
Lanfang Zhang, Mingjuan Zhang, +6 authors, Meiling Gu.
Ann Transl Med, 2020 Dec 15; 8(22). PMID: 33313271    Free PMC article.
T Cell Dysfunction in Cancer.
Daniela S Thommen, Ton N Schumacher.
Cancer Cell, 2018 Apr 11; 33(4). PMID: 29634943    Free PMC article.
Highly Cited. Review.
Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.
James C Lee, Sadaf Mehdizadeh, +5 authors, Jeffrey A Bluestone.
Sci Immunol, 2020 Oct 04; 5(52). PMID: 33008914    Free PMC article.
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells.
Silke Eisinger, Dhifaf Sarhan, +17 authors, Mikael C I Karlsson.
Proc Natl Acad Sci U S A, 2020 Nov 25; 117(50). PMID: 33229588    Free PMC article.
Modulating the Tumour Microenvironment by Intratumoural Injection of Pattern Recognition Receptor Agonists.
Olivia K Burn, Kef K Prasit, Ian F Hermans.
Cancers (Basel), 2020 Dec 24; 12(12). PMID: 33352882    Free PMC article.
CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Stephen T Muth, May Tun Saung, +3 authors, Lei Zheng.
Cancer Lett, 2020 Dec 04; 499. PMID: 33271264    Free PMC article.
The Current Landscape of Antibody-based Therapies in Solid Malignancies.
Ashu Shah, Sanchita Rauth, +6 authors, Surinder K Batra.
Theranostics, 2021 Jan 05; 11(3). PMID: 33391547    Free PMC article.
Cell by cell immuno- and cancer marker profiling of non-small cell lung cancer tissue: Checkpoint marker expression on CD103+, CD4+ T-cells predicts circulating tumor cells.
Xiaoyang Wang, Maria Jaimes, +7 authors, Bruce K Patterson.
Transl Oncol, 2020 Nov 21; 14(1). PMID: 33217647    Free PMC article.
Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.
Spencer E Brightman, Martin S Naradikian, Aaron M Miller, Stephen P Schoenberger.
J Leukoc Biol, 2020 Mar 15; 107(4). PMID: 32170883    Free PMC article.
Domain binding and isotype dictate the activity of anti-human OX40 antibodies.
Jordana Griffiths, Khiyam Hussain, +18 authors, Mark S Cragg.
J Immunother Cancer, 2021 Jan 12; 8(2). PMID: 33428585    Free PMC article.
Tumor-associated myeloid cells: diversity and therapeutic targeting.
Alberto Mantovani, Federica Marchesi, +2 authors, Paola Allavena.
Cell Mol Immunol, 2021 Jan 22; 18(3). PMID: 33473192    Free PMC article.
Impact of the microbiome on cancer progression and response to anti-cancer therapies.
Claire Buchta Rosean, Tzu-Yu Feng, Francesca N Azar, Melanie R Rutkowski.
Adv Cancer Res, 2019 Jun 17; 143. PMID: 31202360    Free PMC article.
IFN-γ and CD38 in Hyperprogressive Cancer Development.
Stefania Angelicola, Francesca Ruzzi, +6 authors, Arianna Palladini.
Cancers (Basel), 2021 Jan 21; 13(2). PMID: 33467713    Free PMC article.
CAR T cells in solid tumors: challenges and opportunities.
Faroogh Marofi, Roza Motavalli, +12 authors, Farhad Motavalli Khiavi.
Stem Cell Res Ther, 2021 Jan 27; 12(1). PMID: 33494834    Free PMC article.
Regulatory T Cells: Concept, Classification, Phenotype, and Biological Characteristics.
Yang Du, Qiannan Fang, Song-Guo Zheng.
Adv Exp Med Biol, 2021 Feb 02; 1278. PMID: 33523440
Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy.
H Ryan Kolb, Nicholas Borcherding, Weizhou Zhang.
Adv Exp Med Biol, 2021 Feb 02; 1278. PMID: 33523451
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
Darren J Schofield, Jennifer Percival-Alwyn, +18 authors, Michael Oberst.
MAbs, 2021 Jan 06; 13(1). PMID: 33397194    Free PMC article.
Influence of single nucleotide polymorphisms among cigarette smoking and non-smoking patients with coronary artery disease, urinary bladder cancer and lung cancer.
Nongnit Laytragoon Lewin, Jan-Erik Karlsson, +9 authors, Freddi Lewin.
PLoS One, 2021 Jan 29; 16(1). PMID: 33507988    Free PMC article.
Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers.
Paola Trono, Antonella Sistigu, +2 authors, Paola Nisticò.
Emerg Top Life Sci, 2017 Dec 12; 1(5). PMID: 33525801    Free PMC article.
Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors.
Nayoung Kim, Dong-Hee Lee, +5 authors, Hun Sik Kim.
BMB Rep, 2020 Dec 11; 54(1). PMID: 33298244    Free PMC article.
HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression.
Xiaolei Li, Xiao Su, +8 authors, Yufang Shi.
Oncogene, 2021 Feb 11; 40(10). PMID: 33564072    Free PMC article.
Immune Privilege: The Microbiome and Uveitis.
Christine Mölzer, Jarmila Heissigerova, +2 authors, John V Forrester.
Front Immunol, 2021 Feb 12; 11. PMID: 33569055    Free PMC article.
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.
Zena N Willsmore, Robert J Harris, +21 authors, Sophia N Karagiannis.
Front Immunol, 2021 Feb 12; 11. PMID: 33569063    Free PMC article.
Modulation of regulatory T cell function and stability by co-inhibitory receptors.
Liliana E Lucca, Margarita Dominguez-Villar.
Nat Rev Immunol, 2020 Apr 10; 20(11). PMID: 32269380
Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion via Mechanisms Similar and Distinct From CTLA-4 and PD-1.
Divij Mathew, Raul M Torres.
Front Immunol, 2021 Feb 16; 11. PMID: 33584637    Free PMC article.
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes.
Samuel I Kim, Christopher R Cassella, Katelyn T Byrne.
Front Immunol, 2021 Feb 19; 11. PMID: 33597954    Free PMC article.
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.
Allan Relecom, Maysaloun Merhi, +4 authors, Said Dermime.
J Exp Clin Cancer Res, 2021 Feb 20; 40(1). PMID: 33602280    Free PMC article.
Isotype selection for antibody-based cancer therapy.
N Vukovic, A van Elsas, J S Verbeek, D M W Zaiss.
Clin Exp Immunol, 2020 Nov 07; 203(3). PMID: 33155272    Free PMC article.
A T cell repertoire timestamp is at the core of responsiveness to CTLA-4 blockade.
Hagit Philip, Tom Snir, +3 authors, Sol Efroni.
iScience, 2021 Feb 20; 24(2). PMID: 33604527    Free PMC article.
Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments.
Adrien Procureur, Audrey Simonaggio, +2 authors, Yann-Alexandre Vano.
Cancers (Basel), 2021 Feb 12; 13(4). PMID: 33567530    Free PMC article.
Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response.
Elisa C Toffoli, Abdolkarim Sheikhi, +6 authors, Tanja D de Gruijl.
Cancers (Basel), 2021 Feb 13; 13(4). PMID: 33572396    Free PMC article.
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Isabelle Solomon, Maria Amann, +29 authors, Sergio A Quezada.
Nat Cancer, 2021 Mar 02; 1(12). PMID: 33644766    Free PMC article.
Beyond immune checkpoint blockade: emerging immunological strategies.
Shawn P Kubli, Thorsten Berger, +2 authors, Tak W Mak.
Nat Rev Drug Discov, 2021 Mar 10; 20(12). PMID: 33686237
The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies.
Jose M González-Navajas, Dengxia Denise Fan, +4 authors, Jongdae Lee.
Front Immunol, 2021 Mar 16; 12. PMID: 33717139    Free PMC article.
Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
Franziska K Krebs, Emily R Trzeciak, +6 authors, Andrea Tuettenberg.
Cancer Med, 2021 Jan 16; 10(5). PMID: 33449393    Free PMC article.
Understanding and treating the inflammatory adverse events of cancer immunotherapy.
Michael Dougan, Adrienne M Luoma, Stephanie K Dougan, Kai W Wucherpfennig.
Cell, 2021 Mar 07; 184(6). PMID: 33675691    Free PMC article.
Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.
Enyu Lin, Xuechao Liu, +5 authors, Yuming Yu.
Front Immunol, 2021 Mar 23; 12. PMID: 33746989    Free PMC article.
The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses.
Guanglin Cui.
Front Oncol, 2021 Mar 26; 11. PMID: 33763344    Free PMC article.
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.
Guangna Liu, Wei Rui, Xueqiang Zhao, Xin Lin.
Cell Mol Immunol, 2021 Apr 01; 18(5). PMID: 33785843    Free PMC article.
Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report.
Periklis Kyriazis, Abhinav Tiwary, +2 authors, Gregory Braden.
J Med Case Rep, 2021 Apr 04; 15(1). PMID: 33810799    Free PMC article.
OX40 as a novel target for the reversal of immune escape in colorectal cancer.
Lin-Hai Yan, Xiao-Liang Liu, +3 authors, Wei-Zhong Tang.
Am J Transl Res, 2021 Apr 13; 13(3). PMID: 33841630    Free PMC article.
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy.
Benedetta Apollonio, Nikolaos Ioannou, Despoina Papazoglou, Alan G Ramsay.
Front Oncol, 2021 Apr 13; 11. PMID: 33842331    Free PMC article.
Abnormal alternative splicing promotes tumor resistance in targeted therapy and immunotherapy.
Kun Deng, Jingwei Yao, +2 authors, Jianhong Zuo.
Transl Oncol, 2021 Mar 29; 14(6). PMID: 33774500    Free PMC article.
Cancer Vaccines, Adjuvants, and Delivery Systems.
Samantha J Paston, Victoria A Brentville, Peter Symonds, Lindy G Durrant.
Front Immunol, 2021 Apr 17; 12. PMID: 33859638    Free PMC article.
Immunotherapy for Prostate Cancer.
Nicholas J Venturini, Charles G Drake.
Cold Spring Harb Perspect Med, 2018 Sep 12; 9(5). PMID: 30201787    Free PMC article.
Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ.
Renske J E van den Bijgaart, Fabian Schuurmans, +3 authors, Gosse J Adema.
Front Immunol, 2021 May 04; 12. PMID: 33936033    Free PMC article.
STARTRAC analyses of scRNAseq data from tumor models reveal T cell dynamics and therapeutic targets.
Dev Bhatt, Boxi Kang, +13 authors, Wenjun Ouyang.
J Exp Med, 2021 Apr 27; 218(6). PMID: 33900375    Free PMC article.
Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations.
Mark A Perazella, Ben Sprangers.
Clin Kidney J, 2021 May 11; 14(5). PMID: 33970161    Free PMC article.
Local Depletion of Immune Checkpoint Ligand CTLA4 Expressing Cells in Tumor Beds Enhances Antitumor Host Immunity.
Ryuhei Okada, Takuya Kato, +4 authors, Hisataka Kobayashi.
Adv Ther (Weinh), 2021 May 18; 4(5). PMID: 33997271    Free PMC article.
Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights.
Sandeep Kumar, Sunil Kumar Singh, Basabi Rana, Ajay Rana.
Drug Discov Today, 2021 Jan 16; 26(4). PMID: 33450394    Free PMC article.
A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells.
Katherine E Harris, Kyle J Lorentsen, +18 authors, Nathan D Trinklein.
Sci Rep, 2021 May 21; 11(1). PMID: 34011961    Free PMC article.
Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy.
Nicholas C DeVito, Michael Sturdivant, +8 authors, Brent A Hanks.
Cell Rep, 2021 May 06; 35(5). PMID: 33951424    Free PMC article.
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Jennifer L Guerriero, Alaba Sotayo, +11 authors, Anthony Letai.
Nature, 2017 Mar 09; 543(7645). PMID: 28273064    Free PMC article.
Highly Cited.
Nanotechnology synergized immunoengineering for cancer.
Deepak S Chauhan, Anupam Dhasmana, +6 authors, Murali M Yallapu.
Eur J Pharm Biopharm, 2021 Mar 29; 163. PMID: 33774162    Free PMC article.
Differential and sequential immunomodulatory role of neutrophils and Ly6Chi inflammatory monocytes during antiviral antibody therapy.
Jennifer Lambour, Mar Naranjo-Gomez, Myriam Boyer-Clavel, Mireia Pelegrin.
Emerg Microbes Infect, 2021 Apr 17; 10(1). PMID: 33858301    Free PMC article.
DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression.
Naidong Zhang, Rongping Yin, +13 authors, Yuhui Huang.
Proc Natl Acad Sci U S A, 2021 May 27; 118(22). PMID: 34035167    Free PMC article.
Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells.
Brandon J Burbach, Stephen D O'Flanagan, +11 authors, Yoji Shimizu.
Nat Commun, 2021 Jun 25; 12(1). PMID: 34162858    Free PMC article.
Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.
Simon Eschweiler, James Clarke, +14 authors, Pandurangan Vijayanand.
Nat Immunol, 2021 Jun 26; 22(8). PMID: 34168370    Free PMC article.
Single-cell analyses reveal suppressive tumor microenvironment of human colorectal cancer.
Yan Mei, Weiwei Xiao, +15 authors, Guangshuai Jia.
Clin Transl Med, 2021 Jun 30; 11(6). PMID: 34185431    Free PMC article.
Explant Modeling of the Immune Environment of Head and Neck Cancer.
Shay Sharon, Thomas Duhen, +9 authors, Michael Gough.
Front Oncol, 2021 Jul 06; 11. PMID: 34221953    Free PMC article.
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.
Elena Shklovskaya, Helen Rizos.
Int J Mol Sci, 2021 Jul 03; 22(13). PMID: 34201655    Free PMC article.
Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity.
Alicia Teijeira Crespo, Stephanie Burnell, +7 authors, Alan L Parker.
Immunology, 2021 Feb 28; 163(4). PMID: 33638871    Free PMC article.
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy.
Bonnie L Russell, Selisha A Sooklal, +2 authors, Monde Ntwasa.
Front Oncol, 2021 Jul 17; 11. PMID: 34268109    Free PMC article.
Type 1 conventional dendritic cells and interferons are required for spontaneous CD4+ and CD8+ T-cell protective responses to breast cancer.
Raphaël Mattiuz, Carine Brousse, +9 authors, Karine Crozat.
Clin Transl Immunology, 2021 Jul 20; 10(7). PMID: 34277006    Free PMC article.
Emerging Technologies for Non-invasive Monitoring of Treatment Response to Immunotherapy for Brain Tumors.
Dimitrios Mathios, Siddhartha Srivastava, +2 authors, Michael Lim.
Neuromolecular Med, 2021 Jul 24;. PMID: 34297308
The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy.
Reza Bayat Mokhtari, Manpreet Sambi, +7 authors, Myron R Szewczuk.
Cancers (Basel), 2021 Jul 25; 13(14). PMID: 34298809    Free PMC article.
Alternol triggers immunogenic cell death via reactive oxygen species generation.
Changlin Li, Ying Zhang, +4 authors, Benyi Li.
Oncoimmunology, 2021 Aug 06; 10(1). PMID: 34350063    Free PMC article.
Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Jessica Castrillon Lal, Madeline G Townsend, +7 authors, Jennifer L Guerriero.
Breast Cancer Res, 2021 Aug 07; 23(1). PMID: 34353349    Free PMC article.
Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade.
Rachel L Y Ho, Ivy A W Ho.
Cancers (Basel), 2021 Aug 08; 13(15). PMID: 34359588    Free PMC article.
Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors.
Emily F Davis-Marcisak, Allison A Fitzgerald, +5 authors, Elana J Fertig.
Genome Med, 2021 Aug 12; 13(1). PMID: 34376232    Free PMC article.
Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens.
Rhonda C Kines, Cynthia D Thompson, +4 authors, John T Schiller.
Cancer Immunol Res, 2021 Apr 16; 9(6). PMID: 33853825    Free PMC article.
The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives.
Aymara Sancho-Araiz, Victor Mangas-Sanjuan, Iñaki F Trocóniz.
Pharmaceutics, 2021 Aug 11; 13(7). PMID: 34371708    Free PMC article.
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
Guoying Zhou, Patrick P C Boor, +2 authors, Jaap Kwekkeboom.
Br J Cancer, 2021 Aug 18; 126(1). PMID: 34400801    Free PMC article.
LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells.
Takahiro Yamazaki, Erik Wennerberg, +8 authors, Lorenzo Galluzzi.
Oncoimmunology, 2021 Aug 20; 10(1). PMID: 34408925    Free PMC article.
Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy.
David M Francis, Margaret P Manspeaker, +6 authors, Susan N Thomas.
Sci Transl Med, 2020 Oct 02; 12(563). PMID: 32998971    Free PMC article.
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Firas Hamdan, Erkko Ylösmäki, +18 authors, Vincenzo Cerullo.
J Immunother Cancer, 2021 Aug 08; 9(8). PMID: 34362830    Free PMC article.
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Hiroyoshi Nishikawa, Shohei Koyama.
J Immunother Cancer, 2021 Aug 01; 9(7). PMID: 34330764    Free PMC article.
Identification of Autophagy- and Ferroptosis-Related lncRNAs Functioned through Immune-Related Pathways in Head and Neck Squamous Carcinoma.
Qi Guo, Xuehan Zhang, Tao Shen, Xiangting Wang.
Life (Basel), 2021 Aug 28; 11(8). PMID: 34440579    Free PMC article.
Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
Masatsugu Miyashita, Teruki Shimizu, Eishi Ashihara, Osamu Ukimura.
Int J Mol Sci, 2021 Aug 28; 22(16). PMID: 34445615    Free PMC article.
Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation.
Kotaro Sugawara, Miwako Iwai, +3 authors, Tomoki Todo.
Mol Ther Oncolytics, 2021 Sep 14; 22. PMID: 34514094    Free PMC article.
Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy.
Muhammad Khan, Sumbal Arooj, Hua Wang.
Front Immunol, 2021 Sep 18; 12. PMID: 34531847    Free PMC article.
Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle.
Aikaterini Hatzioannou, Athina Boumpas, +4 authors, Panayotis Verginis.
Front Immunol, 2021 Sep 21; 12. PMID: 34539668    Free PMC article.
GARP: A Key Target to Evaluate Tumor Immunosuppressive Microenvironment.
Alexanne Bouchard, Bertrand Collin, +2 authors, Evelyne Kohli.
Biology (Basel), 2021 Sep 29; 10(9). PMID: 34571713    Free PMC article.
Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages.
Mariana Reis-Sobreiro, Afonso Teixeira da Mota, Carolina Jardim, Karine Serre.
Cells, 2021 Sep 29; 10(9). PMID: 34572013    Free PMC article.
NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images.
Virginia Liberini, Annapaola Mariniello, +7 authors, Désirée Deandreis.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572771    Free PMC article.
Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade.
Yasuhiro Kanda, Taku Okazaki, Tomoya Katakai.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572844    Free PMC article.
Targeting the spectrum of immune checkpoints in prostate cancer.
Laura A Sena, Samuel R Denmeade, Emmanuel S Antonarakis.
Expert Rev Clin Pharmacol, 2021 Jul 16; 14(10). PMID: 34263692    Free PMC article.
CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells.
Myung-Chul Kim, Nicholas Borcherding, +32 authors, Weizhou Zhang.
Nat Commun, 2021 Oct 03; 12(1). PMID: 34599187    Free PMC article.
Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies.
Khiyam Hussain, Mark S Cragg, Stephen A Beers.
Cancers (Basel), 2021 Oct 14; 13(19). PMID: 34638388    Free PMC article.
CD200 Blockade Modulates Tumor Immune Microenvironment but Fails to Show Efficacy in Inhibiting Tumor Growth in a Murine Model of Melanoma.
Fatemeh Talebian, Jianyu Yu, +3 authors, Xue-Feng Bai.
Front Cell Dev Biol, 2021 Oct 26; 9. PMID: 34692697    Free PMC article.
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness.
Daniel Hirschhorn, Allison Betof Warner, +11 authors, Jedd D Wolchok.
JCI Insight, 2021 Oct 23; 6(20). PMID: 34676831    Free PMC article.
Engineering a variant of IL-17RA with high binding affinity to IL-17A for optimized immunotherapy.
Fatemeh Armaghan, Zahra Hajihassan.
Biotechnol Rep (Amst), 2021 Nov 13; 32. PMID: 34765462    Free PMC article.
Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response.
Yosuke Sato, Yu Fu, +2 authors, Michael H Shaw.
BMC Cancer, 2021 Nov 15; 21(1). PMID: 34774008    Free PMC article.
Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation.
Lilia Bardoscia, Nadia Pasinetti, +2 authors, Angela Sardaro.
Front Pharmacol, 2021 Nov 19; 12. PMID: 34790123    Free PMC article.
Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity.
Deyong Song, Xiu Liu, +12 authors, Changlin Dou.
Sci Rep, 2021 Nov 27; 11(1). PMID: 34824364    Free PMC article.
[Clinical Trial Progress and Application of Immune Checkpoint Inhibitors 
in the Treatment of Small Cell Lung Cancer].
Huiqiu Zhang, Xiyang Li, Xichuan Li, Yanjun Su.
Zhongguo Fei Ai Za Zhi, 2021 Nov 22; 24(11). PMID: 34802211    Free PMC article.
Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer.
Jianyu Liu, Xueying Wang, +3 authors, Zhigao Li.
Front Oncol, 2021 Dec 07; 11. PMID: 34868991    Free PMC article.
Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy.
R R Maniyar, S Chakraborty, +4 authors, R K Tiwari.
Adv Exp Med Biol, 2021 Dec 11; 1350. PMID: 34888847
Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story.
Mauro Cataldi, Federica Manco, Giovanni Tarantino.
Int J Mol Sci, 2021 Dec 11; 22(23). PMID: 34884762    Free PMC article.
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Rui Xing, Jinping Gao, Qi Cui, Qian Wang.
Front Immunol, 2021 Dec 14; 12. PMID: 34899747    Free PMC article.
Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.
Takuro Saito, Koji Kurose, +11 authors, Hisashi Wada.
Nagoya J Med Sci, 2021 Dec 18; 83(4). PMID: 34916725    Free PMC article.
Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop.
Francesco Marangoni, Ademi Zhakyp, +10 authors, Thorsten R Mempel.
Cell, 2021 Jun 23; 184(15). PMID: 34157302    Free PMC article.
The foundations of immune checkpoint blockade and the ipilimumab approval decennial.
Alan J Korman, Sarah C Garrett-Thomson, Nils Lonberg.
Nat Rev Drug Discov, 2021 Dec 24;. PMID: 34937915
Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review.
Joosje C Baltussen, Marij J P Welters, +7 authors, Nienke A de Glas.
Cancers (Basel), 2021 Dec 25; 13(24). PMID: 34944986    Free PMC article.
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Elena Goleva, Taras Lyubchenko, +3 authors, Jeffrey A Kern.
Ann Allergy Asthma Immunol, 2021 Mar 16; 126(6). PMID: 33716146    Free PMC article.
Resistance to Immunotherapy: Mechanisms and Means for Overcoming.
Mohamad A Salkeni, John Y Shin, James L Gulley.
Adv Exp Med Biol, 2022 Jan 02; 1342. PMID: 34972962
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.
Somayeh Vafaei, Angelina O Zekiy, +4 authors, Majid Zamani.
Cancer Cell Int, 2022 Jan 05; 22(1). PMID: 34980128    Free PMC article.
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Nicola J Mason, Nicholas Chester, +6 authors, Don L Siegel.
MAbs, 2021 Dec 04; 13(1). PMID: 34856888    Free PMC article.
Membrane tension sensing molecule-FNBP1 is a prognostic biomarker related to immune infiltration in BRCA, LUAD and STAD.
Zixuan Wang, Zixin Tian, Xi Song, Jun Zhang.
BMC Immunol, 2022 Jan 10; 23(1). PMID: 34998385    Free PMC article.
Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy.
Myriam Ben Khelil, Yann Godet, +3 authors, Romain Loyon.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008422    Free PMC article.
Mechanisms of immune checkpoint inhibitor-mediated liver injury.
Layla Shojaie, Myra Ali, Andrea Iorga, Lily Dara.
Acta Pharm Sin B, 2022 Jan 14; 11(12). PMID: 35024302    Free PMC article.
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.
Golnaz Morad, Beth A Helmink, Padmanee Sharma, Jennifer A Wargo.
Cell, 2021 Oct 09; 184(21). PMID: 34624224    Free PMC article.
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Ming Yi, Xiaoli Zheng, +3 authors, Kongming Wu.
Mol Cancer, 2022 Jan 23; 21(1). PMID: 35062949    Free PMC article.
TGFβ2 Induces the Soluble Isoform of CTLA-4 - Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma.
Rahul C Khanolkar, Chu Zhang, +11 authors, Frank James Ward.
Front Immunol, 2022 Jan 25; 12. PMID: 35069536    Free PMC article.
PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm.
Kai-Fu Zheng, Yu-Jian Liu, +12 authors, Jin-Bo Zhao.
Transl Lung Cancer Res, 2022 Jan 25; 10(12). PMID: 35070765    Free PMC article.
Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation.
Kelly Walkovich, James A Connelly.
Hematology Am Soc Hematol Educ Program, 2021 Dec 11; 2021(1). PMID: 34889406    Free PMC article.
Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?
Clara Martori, Lidia Sanchez-Moral, +4 authors, Maria-Rosa Sarrias.
Cancers (Basel), 2022 Jan 22; 14(2). PMID: 35053602    Free PMC article.
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.
Monika Semmrich, Jean-Baptiste Marchand, +15 authors, Björn Frendéus.
J Immunother Cancer, 2022 Jan 22; 10(1). PMID: 35058324    Free PMC article.
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
Olivier Michielin, Aly-Khan Lalani, +2 authors, Solange Peters.
J Immunother Cancer, 2022 Jan 27; 10(1). PMID: 35078922    Free PMC article.
Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1.
Yuwei Hao, Matthew C Cook.
Front Immunol, 2022 Feb 15; 12. PMID: 35154081    Free PMC article.
Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.
Álvaro Padrón, Vincent Hurez, +8 authors, Tyler J Curiel.
Exp Gerontol, 2018 Jan 13; 105. PMID: 29326088    Free PMC article.
Identification and Characterization of Immunogene-Related Alternative Splicing Patterns and Tumor Microenvironment Infiltration Patterns in Breast Cancer.
Shuang Guo, Xinyue Wang, +12 authors, Shangwei Ning.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35158863    Free PMC article.
Immune Checkpoint Blockade Augments Changes Within Oncolytic Virus-induced Cancer MHC-I Peptidome, Creating Novel Antitumor CD8 T Cell Reactivities.
Youra Kim, Prathyusha Konda, +3 authors, Shashi Gujar.
Mol Cell Proteomics, 2021 Dec 19; 21(2). PMID: 34922008    Free PMC article.
Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.
Yosuke Sato, Cierra N Casson, +14 authors, Michael H Shaw.
Cancer Immunol Immunother, 2022 Mar 04;. PMID: 35237846
Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.
Meng-Ju Wu, Lei Shi, +30 authors, Nabeel Bardeesy.
Cancer Discov, 2021 Dec 02; 12(3). PMID: 34848557    Free PMC article.
An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
Xin Chen, Liu Xue, +23 authors, Tong Zhang.
Front Immunol, 2022 Mar 12; 13. PMID: 35273608    Free PMC article.
Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering.
Franziska Heckel, Anna H Turaj, +12 authors, Sean H Lim.
Commun Biol, 2022 Mar 16; 5(1). PMID: 35288635    Free PMC article.
Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Qi Li, Mengran Cao, +9 authors, Jinzhang Chen.
Front Oncol, 2022 Mar 15; 12. PMID: 35280760    Free PMC article.
Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy.
Megan M Y Hong, Saman Maleki Vareki.
Cancers (Basel), 2022 Mar 26; 14(6). PMID: 35326731    Free PMC article.
Combinations of radiotherapy with immunotherapy in cervical cancer.
Xiaojing Yang, Hanru Ren, Jie Fu.
J Cancer, 2022 Apr 05; 13(5). PMID: 35371317    Free PMC article.
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.
Khiyam Hussain, Rena Liu, +28 authors, Mark S Cragg.
J Exp Clin Cancer Res, 2022 Apr 09; 41(1). PMID: 35392965    Free PMC article.
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Adel Naimi, Rebar N Mohammed, +11 authors, Ehsan Razeghian.
Cell Commun Signal, 2022 Apr 09; 20(1). PMID: 35392976    Free PMC article.
Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?
Michael Kuske, Maximilian Haist, +2 authors, Matthias Bros.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406483    Free PMC article.
Enhanced T-Cell Priming and Improved Anti-Tumor Immunity through Lymphatic Delivery of Checkpoint Blockade Immunotherapy.
Carolina Mantilla-Rojas, Fred C Velasquez, +4 authors, Eva M Sevick-Muraca.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406595    Free PMC article.
Tipping the balance: inhibitory checkpoints in intestinal homeostasis.
Maria E Joosse, Iris Nederlof, Lucy S K Walker, Janneke N Samsom.
Mucosal Immunol, 2018 Dec 01; 12(1). PMID: 30498201
The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy.
Cathrin L C Gudd, Lucia A Possamai.
Cancers (Basel), 2022 Apr 24; 14(8). PMID: 35454819    Free PMC article.
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.
Daniel Ronen, Aseel Bsoul, +4 authors, Rabea Asleh.
Vaccines (Basel), 2022 Apr 24; 10(4). PMID: 35455289    Free PMC article.
The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy.
Peter John, Marc C Pulanco, +4 authors, Xingxing Zang.
Nat Commun, 2022 May 07; 13(1). PMID: 35523809